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ABSTRACT 
 
Since ancient times, indigenous plants have been used by traditional healers for treating 
various ailments. Sutherlandia frutescens is one of the most commonly used medicinal plants 
of southern Africa. This widely distributed plant has been traditionally used to treat cancer 
and HIV patients; however scientific validation is still in high demand. This research aimed to 
phytochemically characterise the various extracts prepared and to determine if any 
chemotypes were present. Subsequent biological characterisation was carried out to 
preliminary ascertain whether this medicinal plant could have anti-cancer and/or immune-
modulating properties and which compounds might be responsible for these actions. 
Various traditional and organic extracts were prepared. Extracts, fractions and compounds 
generated were analysed and chemical profiles obtained. Column chromatographic techniques 
were used to isolate and purify compounds and structure elucidation was carried out using 
various analytical techniques. Sulforhodamine B and cytometric bead array assays were 
performed to determine the biological activities of samples generated. 
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CHAPTER 1 
INTRODUCTION 
 
1.1 MEDICINAL PLANTS 
Although one can be gifted genetically with a powerful immune system nutrients help to 
ensure optimal development of one‟s immune system. Plants constitute the base of the food 
chain and provide the most valuable source of natural nutrients; in addition, constituents of 
medicinal importance are also present in plants (Anonymous, 2000). 
Plants used for medicinal purposes contribute significantly to the development of major 
medical drugs that are used today. Most of our common medicines have compounds extracted 
from plants as their primary active ingredients and many have also provided blueprints for 
synthetic or partially synthetic drugs (Simpson and Ogorzaly, 2001).
 
A major part of using plants as medicines involves the use of plant extracts or their active 
principles. Medicinal plants and plant-derived medicines are widely used in different 
traditions all over the world and they are becoming increasingly popular in modern scientific 
communities as natural alternatives to synthetic chemicals (Van Wyk and Wink, 2004). Many 
plants synthesize substances that are useful to the maintenance of health in humans and other 
animals. These include aromatic substances, most of which are phenols or their oxygen-
substituted derivatives such as tannins. In many cases, substances such as alkaloids serve as 
plant defence mechanisms against predation by microorganisms, insects and herbivores. In 
general many herbs and spices are used for food seasoning which also underlies useful 
medicinal properties (Lai, 2004).  
A single plant can be viewed from a purely scientific perspective as a biosynthetic facility 
manufacturing a large number of molecules from simple nutrients, water, carbon dioxide and 
solar energy. The resulting chemistry is quite complex and includes all the final molecules in 
the biosynthetic pathway, together with their precursors. Molecules that are produced when 
an alternative pathway has been activated and are not required in primary metabolic 
processes are known as secondary metabolites, and some are believed to have evolved to 
form part of the plant‟s defence mechanism. Many of these secondary metabolites have 
biological activities that can be assayed in the laboratory, providing a scientific rationale for 
2 
the use of the particular plant. In some cases isolated active compounds are subsequently 
channelled into drug development regimes and eventually commercialised. In this regard, it 
has been estimated that about a quarter of all modern drugs were originally derived from 
plant sources with relatively complex or advanced characteristics (Kinghorn and Balandrin, 
1993). 
Well-known examples of plant-derived medicines include quinine (from Chincona species), 
morphine and codeine (from Opium species), colchicines (from Colchicum autumnale), 
atropine (from the Solanaceae family), reserpine (from Rauwolfa serpentine), salicin (from 
Salix alba) and digoxin (from Digitalis purpurea). Important advances in anti-cancer drugs 
such as taxol (from Taxus brevifolia) and vincristine (from Catharanthus roseus) have been 
developed from plants (Dewick, 2002; Simpson and Ogorzaly, 2001; Van Wyk and Wink, 
2004). 
The vast knowledge of herbal remedies in traditional cultures is believed to have developed 
through trial and error over many centuries, with the most important cures being carefully 
passed on via the verbal route from one generation to the next (Van Wyk and Wink, 2004). 
One of the spin-offs derived from such a plethora of traditional knowledge, is that many new 
and important remedies are still being discovered. 
 
1.2 MEDICINAL PLANTS OF SOUTHERN AFRICA 
Traditional medicine in Africa is perhaps the oldest and most diverse of all medicine systems 
(Van Wyk and Wink, 2004). Southern Africa is rich in plant and cultural diversity and 
various endemic and foreign plants today are used for a variety of medicinal purposes. The 
study of the use of plants by local people is widely dispersed in southern Africa and the 
interactions of these plants with biological systems needs to be continuously investigated. 
Collection and documentation of this indigenous knowledge are required to prevent loss to 
future generations (Van Wyk and Gericke, 2000) and to guide future medicinal 
investigations. The use of traditional medicines by Africans is widespread and promoted by 
Ministries of Health in several African nations, including South Africa. Two herbal remedies 
(Hypoxis hemerocallidea and Sutherlandia frutescens), are currently recommended by the 
South Africa Ministry of Health for management of many ailments, including cancer and 
infection with human immunodeficiency virus (HIV) (Mills, Cooper et al., 2005). Both of 
3 
these remedies have shown the potential for drug interactions, but efforts should be made by 
health professionals to provide validated information to traditional healers and their patients 
on the careful use of herbal medicines (Mills, Foster et al., 2005). To date no pure isolated 
compound from Sutherlandia has been developed into a marketable drug. However, a 
number of phytopharmaceuticals (pharmaceuticals made from plant extracts standardised 
using active compounds) have been developed and commercialised (such as „Power-Your-
Life‟ products from Parceval pharmaceuticals) (www.parceval.co.za). 
Extracts from around 4 000 species of plants have been used for medicinal purposes in 
southern Africa. Tonic plants have multiple functions in the human body, and act in healthy 
individuals by maintaining and supporting general physical and mental health. When 
individuals are ill, or on the way to recovery, tonics can assist in restoring their health and are 
believed to tone the body‟s organ systems as well as improving immune function. These 
substances act by enhancing body metabolism, including secretion and excretion of waste 
products, improving digestion and may also have a mild purgative effect. Some tonics are 
effective adaptogens, significantly enhancing the body‟s ability to adapt to physical and 
emotional stress (Van Wyk and Gericke, 2000).  
 In general, most of these herbal and traditional medicines are not well researched, poorly 
regulated and may even contain contaminated products which could produce adverse effects 
(Mills, Cooper et al., 2005). There is a growing appreciation for the potential of natural tonics 
in maintaining and supporting health, particularly where modern allopathic medicine is 
concerned. This has come about mainly as a result of scientific investigations into the 
activities, pharmacology and chemistry of some well known adaptogenic plants, including 
ginseng (Panax ginseng), American ginseng (Panax quinquefolium), Siberian ginseng 
(Eleutherococcus senticosus) and Indian ginseng (Withania somnifera). One of the most 
significant adaptogenic plants from southern Africa belongs to the Sutherlandia genus. 
Affordable natural tonics, supported by formal clinical studies, could play an important role 
in improving the quality of life in patients with cancer, tuberculosis, HIV/AIDS and other 
serious health conditions. In spite of their broad utility and common use, tonics should be 
used responsibly in appropriate doses, as well as for defined durations (Van Wyk and 
Gericke, 2000).  
Indigenous knowledge systems are dynamic and adaptive, and over the last few hundred 
years many introduced plants have been extensively used in southern African medicine, 
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including rue (Ruta graveolens) for a variety of ailments, camphor (Cinnamomum camphora) 
for fever, colds, antiseptic and mild analgesic activity, plus bluegum (Eucalyptus globulus) 
for its use in decongestant medicines (Van Wyk and Gericke, 2000). There are many other 
plants which have an important use in traditional medicines, but the main research focus of 
this study is on one of the above mentioned indigenous plants - Sutherlandia frutescens. 
 
1.3 SUTHERLANDIA FRUTESCENS 
The Sutherlandia plant occurs endemically in South Africa, being widely spread over the 
South Western and Northern Cape Provinces, essentially being found along road verges in the 
drier areas of the country, as indicated in Figure 1.1. The term „sutherlandia‟ refers to a 
shrubby plant that is known by many different names, including  cancer bush, balloon pea 
(English); umnwele (Xhosa); kankerbos, blaasbossie, blaas-ertjie, eendjies, gansiekeurtjie, 
klappers, hoenderbelletjie (Afrikaans); Unwele and Insiswa (Zulu); Musa-Pelo, Motlepelo 
and Phethola (Sotho) (Jackson, 1990). 
 
 
 
Figure 1.1 Geographical distributions of Sutherlandia species throughout South Africa 
(sahealthinfo.org). 
 
Sutherlandia belongs to the family Fabaceae (pea and bean or pod-bearing family) which is 
the second largest flowering plant family in the world. This family contains more than 600 
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genera and 1200 species. In southern Africa, this family is represented by 134 genera and 
more than 1300 species (Jackson, 1990). There are five Sutherlandia species namely, S. 
frutescens, S. microphylla, S. montana, S. tomentosa, and S. humilis. The genus took its name 
from James Sutherland, first Director of the Edinburgh Botanic Garden (Duncan, 2009). 
While field studies over a period of many years have shown that only two species should be 
recognised, along with several geographically separated subspecies (Moshe et al., 1998), this 
classification has not been implemented and many chemical variations are believed to occur, 
involving differences in biological activity and major compounds present in the plant.  
Ecologically, legumes are known for fixing nitrogen in the soil through a symbiotic 
relationship with bacteria. The bacteria infect the roots, forming small growths or nodules. 
Inside the nodules, atmospheric nitrogen, which the plants cannot use, is converted to 
ammonia, which plants can use. The plant supplies sugars for the bacteria; while the bacteria 
provide the biologically useful nitrogen that the plant absorbs (Jackson, 1990). 
Sutherlandia frutescens (see Figure 1.2) is one of the best-known multi-purpose medicinal 
plants. Used as an adaptogenic tonic, the plant‟s therapeutic properties can be attributed to 
subsequent effects on the human body to mobilise immunological and physiological 
resources to help combat diseases, as well as helping to combat physical and mental stress 
(Ojewole, 2008; www.sutherlandia.org). The recommended dose of Sutherlandia frutescens 
in humans is 9 mg per kg body weight per day (Seier et al., 2002). Phyto Nova, of South 
Africa, is a major distributor of both powdered and encapsulated forms of this herb, as well as 
in a gel preparation. Parceval Pharmaceuticals has produced „Power-Your-Life‟ products 
varying from tablets (Reclaim+Protect) to Vaseline (Defend+Protect) and immune-boosting 
syrup with added vitamins (Support+Protect). All are made from Sutherlandia extracts that 
are said to contain the active ingredient SU1 (sutherlandioside B - a cycloartane glycoside) 
(www.parceval.co.za). 
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Figure 1.2 S. frutescens growing in the wild at Goegap Nature Reaserve, Springbok, 
Northern Cape (photo taken by Nial Harding). 
 
1.3.1 A historical aspect of medicinal uses of Sutherlandia 
This plant has been used for hundreds of years by the original inhabitants of the Cape, being 
the Khoi San and Nama people, who used it mainly as a decoction for the washing of wounds 
and also take it internally to reduce fevers. For many hundreds of years, Zulu warriors 
returning from battle used the plant to relax themselves. Grieving widows used it as an anti-
depressant to help them through their loss. The old Zulu word of "insiswa" means "that which 
takes away the dark” refers to the ability of the plant to help with depression and sadness 
(www.plantzafrica.com - Sutherlandia frutescens (L.) R. Br.; Van Wyk and Albrecht, 2008).  
Sutherlandia has long been known and respected as a medicinal plant in southern Africa and 
is regarded as the African adaptogens par excellence. The early colonists regarded it as 
giving successful results in the treatment of chicken pox, stomach problems, internal cancers 
and eye troubles (Watt and Breyer-Brandwjik, 1962). It continues to be used to this day as a 
remedy for the above-mentioned ailments. According to Van Wyk and Gericke (2000), 
tinctures, infusions and decoctions of the leaves and young stems of Sutherlandia have been 
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used to treat colds, flu, asthma, TB, bronchitis, rheumatism, rheumatoid arthritis and osteo-
arthritis, liver problems, haemorrhoids, piles, bladder, uterus and 'women's' complaints, 
diarrhoea and dysentery, stomach ailments, heartburn, peptic ulcers, backache, diabetes, 
varicose veins and inflammation. It is also used in the treatment of mental and emotional 
stress, including irritability, anxiety and depression and is used as a gentle tranquillizer. This 
plant is said to be a useful bitter tonic and that a little taken before meals will aid digestion 
and improve the appetite.  
The Rastafarians also recommend Sutherlandia as a treatment for these medical conditions 
(Dyson, Ashwell and Loedolft, 1998). There is preliminary clinical evidence that it has a 
direct anti-cancer effect in some cancers and that it acts as an immune stimulant 
(www.sutherlandia.org). 
Based on preliminary safety studies, the South African Ministry of Health has concluded that 
extracts from this plant are fit for human consumption. While certain extracts from 
Sutherlandia are said to have immune-boosting activities, their mechanism of action has not 
been comprehensively documented. According to Mills, Cooper et al., (2005), extracts from 
hot water displayed superoxide- as well as hydrogen peroxide scavenging activities that 
ostensibly could account for the anti-oxidant potential and anti-inflammatory properties of S. 
frutescens. Ethanolic extracts were also shown to have an anti-proliferative effect on several 
human tumour cell lines, but did not show significant anti-oxidant activity.  
1.3.2 Pre-isolated compounds from Sutherlandia species 
A number of biologically active compounds occur in high concentrations in extracts from 
Sutherlandia species, such as L-canavanine, D-pinitol, and γ-amino butyric acid (GABA) 
(Van Wyk and Gericke, 2000), including, a novel triterpenoid glycoside (sutherlandioside B) 
(Fu et al., 2008) also known as „SU1‟ (Olivier et al., 2009; Van Wyk and Albrecht, 2008), as 
well as various flavonol glycosides (Fu et al., 2010) have been isolated and characterised. 
Plant extracts have also been shown to contain amino acids, small amounts of saponins, but 
no alkaloids (Van Wyk and Gericke, 2000). A more detailed discussion of these compounds, 
together with some of their activities, follows below. 
1.3.2.1 High levels of free and protein-bound amino acids are common with many 
members of the family Fabaceae (Moshe, 1998). Analyses of leaf extracts from Sutherlandia 
contain high levels of amino acids such as asparagine, proline and arginine. The presence of 
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L-arginine is important, because it acts as an antagonist of L-canavanine that attenuates the 
anti-proliferative activity of canavanine (Van Wyk and Albrecht, 2008). 
1.3.2.2 Canavanine: is frequently found in the seeds of Fabaceae and therefore its 
discovery at high concentrations in extracts from the leaves of Sutherlandia by Moshe 
(1998), was of considerable interest. Canavanine (see Figure 1.3), which is a potent L-
arginine competitor and the L-2-amino-4-guanidino-oxy, is a structural analogue of arginine 
(Mills, Cooper et al., 2005). It has also been shown to have anti-cancer as well as anti-viral 
activity, including inhibition of influenza virus and retroviruses (Green, 1988). As such, this 
finding justifies the traditional use of this plant against cancer; in addition, this also appears 
to be the first known case of a canavanine-containing plant having a well-recorded history of 
use against cancer ( Bence et al., 2002; Crooks and Rosenthal, 1994; Rosenthal, 1997; 
Swaffar, 1995; Van Wyk and Albrecht, 2008). Between 30-40 mg of canavanine can be 
found per dry gram of the leaves (Gericke et al., 2001). Canavanine is an inhibitor of nitric 
oxide synthase, which may be beneficial in certain forms of heart failure (Van Wyk and 
Gericke, 2000). 
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Figure 1.3 Compound 1: Canavanine. 
 
1.3.2.3 Pinitol: is a type of sugar found in many types of legumes and is classified as 
chiro-inositol. It was first found by Snyders (1965), as well as Viljoen (1969) and 
Brummerhoff (1969) in Sutherlandia microphylla leaves. It is also known as 3-O-methyl-D-
chiro-inositol, or 3-0-methyl-1,2,4 cis-3,5,6-trans-hexahydroxy-cyclohexanol (Mills, Cooper 
et al., 2005). The recorded bio-activities of pinitol make it a potentially important compound 
in the context of the traditional uses of Sutherlandia against diabetes and inflammation 
(Moshe, 1998). It has been used for the treatment of wasting in cancer as well as AIDS and is 
a known anti-diabetic agent (Narayanan et al., 1987; Ostlund and Sherman, 1996).  Pinitol 
has also been shown to exert an insulin-like effect (hypoglycaemic effect), resulting in lower 
blood sugar levels and increased availability of glucose for cell metabolism (Bates, Jones and 
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Bailey, 2000). It has also been shown to enhance the retention of creatinine by muscle cells 
(Greenwood et al., 2001), as well as  increasing the ability of the muscle cells to absorb 
glucose, resulting in benefits for sporting enthusiasts, who have concomitant requirements for 
strength and endurance, together with the added benefits of shortened physiological recovery 
times. Pinitol (see Figure 1.4), has also been shown to have a positive effect on muscles 
being able to store carbohydrates, thereby allowing for muscle growth, whilst permitting the 
burning of fat (www.sutherlandia.com). Overall, pinitol therefore seems to play a role in 
regulating cellular energy, resulting in increased energy levels and a reduction in fatigue (Van 
Wyk and Albrecht, 2008). This effect to increase muscle mass, thus has major applications in 
the treatment of wasting syndrome in cancer, HIV/AIDS and tuberculosis. It is not surprising 
therefore, that Sutherlandia has been used on the African continent for generations, to treat 
sufferers of tuberculosis, with impressive results (www.sutherlandia.com).  
It is not only the pinitol present in Sutherlandia that results in all its notable properties.  
Current research has indicated that there is strong evidence to support the interaction of 
pinitol with the other bio-active compounds (www.sutherlandia.com). 
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Figure 1.4 Compound 2: Pinitol. 
 
1.3.2.4 Gamma Amino Butyric Acid (GABA): is a non-essential amino acid and 
inhibitory neurotransmitter that is found in the leaves of Sutherlandia. It is primarily 
synthesized by decarboxylation of glutamate by the enzyme L-glutamic acid-1-decarboxylase 
(Ebadi, 2007). Together with niacinamide (vitamin B3) and inositol, GABA prevents anxiety 
and stress-related neuron messages from reaching the motor centres of the brain. It is thus 
essential for brain metabolism, where it also decreases neuron activity, thus preventing them 
from over-firing (www.vitamins-supplements.org). The presence of GABA also justifies the 
use of S. frutescens in treating anxiety and stress. According to Van Wyk and Gericke (2000), 
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the seeds and leaves have been smoked by labourers and teenagers as a dagga substitute in 
Namaqualand, with the leaves invoking a strong GABA-induced sedative effect when 
smoked.  
According to Braveman and Pfeiffer (1987); Petty et al. (1993) and Petty (1995), GABA has 
been used in the treatment of depression, bipolar disorder, seizures, premenstrual dysphoric 
(feeling depressed) disorder, and anxiety. GABA (see Figure 1.5) also improves sleep cycles, 
as well as having a powerful stabilizing effect on blood pressure. It is a very effective 
analgesic, eliminating pain from chronic conditions such as arthritis and lower back pain. It 
has also been used to treat epilepsy and hypertension, where it is thought to induce 
tranquillity in individuals who have a high activity of manic behaviour and acute agitation 
(Denver Naturopathic Clinic
1
). 
GABA signals the pituitary gland to naturally release Human Growth Hormone (HGH), 
which is widely known for its powerful anabolic (muscle building) effects as well as its 
lipotropic (breakdown and utilization of body fat) effects (Di Luigi et al., 1999). GABA has 
also been found to inhibit tumour cell migration (Ortega, 2003). 
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Figure 1.5 Compound 3: GABA. 
 
1.3.2.5 Sutherlandiosides A to D: The major triterpene, in commercially produced 
Sutherlandia material, is a cycloartane-type triterpene glycoside called sutherlandioside B. At 
least 56 different triterpene glycosides have been detected. According to Van Wyk and 
Albrecht (2008), mixtures of cycloartane-type triterpenoid glycosides have extensive 
geographical variation in South Africa. A study done by Fu et al. (2008), found four 
cycloartane-type triperpenoids which have a bitter tonic activity that stimulates appetite and 
                                                          
1
 1181 S Parker Rd # 101, Denver, CO 80231-2152, United States 
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may contribute to the adaptogenic and immune-boosting effects of Sutherlandia. These four 
compounds are called sutherlandioside A (SU2), B (SU1), C and D. 
Powerful inhibitory effects of cycloartanes with hydroxylation at C-24 and with a 3-oxo 
group have been recorded in an in vivo mouse skin carcinogenesis test performed by Kikuchi 
et al. (2007). This arrangement is found in sutherlandioside B. The structures of the four 
sutherlandiosides A to D are shown in Figure 1.6 as structures 4 to 7. 
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Compound 4: sutherlandioside A  Compound 5: sutherlandioside B 
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Compound 6: sutherlandioside C  Compound 7: sutherlandioside D 
Figure 1.6 Structures of sutherlandiosides A to D are respectively referred to as 
Compounds 4 to 7. 
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1.3.2.6 Flavonol glycosides: Sutherlandia leaves are known to contain at least six 
flavonoids (Moshe, 1998). A study done by Fu et al. (2010) identified four of these to be 
flavonol glycosides named sutherlandin A, B, C and D as shown in Figure 1.7 below. 
Flavonoids are said to have anti-oxidant activity and help to eliminate mutagen and 
carcinogens - which are of value in cancer prevention (Tai et al., 2004).  
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Compound 8: sutherlandin A   Compound 9: sutherlandin B 
Compound 10: sutherlandin C   Compound 11: sutherlandin D 
Figure 1.7 Structures of sutherlandin A to D are referred to as Compounds 8 to 11. 
 
1.3.2.7 Other compounds: hexadecanoic acid, γ-sitosterol, stigmast-4-en-3-one and 
at least three long chain fatty acids have been reported in Sutherlandia (Tai et al., 2004). 
High levels of unidentified polysaccharides have also been reported in aqueous extracts (Van 
Wyk and Albrecht, 2008). 
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1.3.3 Various activities attributed to Sutherlandia extracts 
1.3.3.1 Anti-oxidant potential: Phagocyte-derived reactive oxygen species, such as 
hydrogen peroxide and superoxide radicals, are responsible for pathogenesis of various 
inflammatory conditions. According to Tai et al. (2004), Sutherlandia extracts have been 
shown to contain superoxide- as well as hydrogen peroxide-scavenging activities at low 
concentrations, which account for the anti-inflammatory properties. The anti-inflammatory 
agents have shown to exert chemo-preventive activity by targeting cyclo-oxygenase (COX-
2), a rate-limiting enzyme involved in the inflammatory process. They have also reported that 
ethanolic extracts show anti-proliferative effects on several human tumour cells lines, but no 
anti-oxidant effects. 
1.3.3.2 Analgesic and hypoglycaemic properties: Extracts have been shown to 
contain these properties, which account for the use in type-2 diabetes mellitus (Ojewole, 
2004).  
1.3.3.3 Immune-modulator: Sutherlandia extracts have also been reported to have 
immune-boosting functions in the treatment of HIV/AIDS (Goldblatt and Manning, 2000), 
although the mechanism for this activity has not yet been elucidated. As such, insufficient 
scientific data at present has confounded any attempts to explain the mechanism by which 
extracts from this plant could act on cells of the immune system. 
1.3.3.4 Pharmacological effects and toxicity attributed to Sutherlandia: There has 
been much work done to assess the pharmacokinetics of this medicinal plant. Van Wyk, Van 
Oudtshoorn and Gericke (2009) have indicated that extracts with anti-diabetic effects may be 
due to the presence of pinitol. Similarly, triterpenoids, which have a bitter tonic (amarum) 
activity in stimulating appetite, may also contribute to possible adaptogenic, anti-cachexia, 
immune-boosting and cortico-mimetic effects of Sutherlandia extracts. As previously 
mentioned, Van Wyk, Van Oudtshoorn and Gericke (2009) indicated that canavanine may 
also contribute to the anti-cancer activity. Recently, a new product has been released on the 
market for diabetic patients, containing Sutherlandia plant material in tablet form (Albrecht, 
2011). 
Prevoo, Swart and Swart (2008) have shown that S. frutescens extracts also contain bioactive 
compounds capable of inhibiting the binding of natural substrates (pregnenolone and 
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progesterone), as well as inhibiting the catalytic activity of CYP17 and CYP21 enzymes 
involved in the biosynthesis of steroid hormones. 
In general, from a toxicity perspective, an effective toxicological screen of Sutherlandia 
extracts using a primate model, with doses up to 9 times greater than the recommended 
dosage, did not identify any clinical, haematological or physiological toxicity of this plant 
(MRC and NRF, 2002). 
Johnson et al. (2007) completed a phase I clinical trial in healthy adults to evaluate the safety 
of the dried plant material. It was noted that no side effects were found during or 3 months 
after the trial period. A statistically significant increase in appetite was noted in the treatment 
group, although remained in the normal physiological range. 
1.3.3.5 Anti-cancer effects attributed to Sutherlandia extracts 
Clinical evidence shows that Sutherlandia extracts have direct anti-cancer effects in some 
cancers, together with immune-stimulating properties. Goldblatt and Manning (2000) 
considered these extracts not as a universal cure for cancer, but rather as an improvement-of-
life tonic, wherein the body is assisted to mobilise its own resources to cope with the illness.  
In general, Sutherlandia extracts have been reported to decrease anxiety and irritability, thus 
elevating the mood. Appropriate doses have been reported to dramatically improve appetite 
and weight gain in cancer-wasted patients. Energy levels and exercise tolerance of these 
patients were improved, including an enhancement of their sense of well being. The dose 
administered was generally one tablet (300 mg) twice a day, after meals, but not to be taken 
during pregnancy (http://www.sutherlandia.org).  
Chinkwo (2005) reported that the aqueous extracts could induce apoptosis in cultured 
carcinoma cells and cytotoxicity in neoplastic cells (cervical carcinoma) and also in CHO 
(Chinese Hamster Ovary) cell lines. Induced apoptosis was confirmed by flow cytometric 
analysis. 
1.3.3.6 Anti-HIV effects of Sutherlandia extracts 
Mills, Foster et al. (2005) have reported that the herbal remedy has been recommended for 
HIV management, which was shown to cause an improvement in CD4 counts together with a 
decrease of viral loads in AIDS patients. It is hoped that this treatment regime will delay the 
progression of HIV into AIDS. They further reported that Sutherlandia contained inhibitory 
15 
compounds active against HIV target enzymes. Canavanine, which was found to be present in 
the extracts, has also been reported to have antiviral activity against influenza and 
retroviruses. Sutherlandia extracts have also been reported to have effects on cytochrome 
P450 3A4 metabolism, together with activation of the pregnane X-receptor, which are 
involved in anti-retroviral metabolism. Mills, Foster et al. (2005), have further indicated that 
factors which need to be taken into consideration with HIV patients are risk of treatment 
failure, induced viral resistance or subsequent drug toxicity. They also considered that 
uncontrolled human consumption of Sutherlandia extracts could affect anti-retroviral drug 
metabolism, leading to bi-directional drug interactions and loss of therapeutic efficacy.  
Sutherlandia has also recently been shown to interact with the permeability glycoprotein (P-
gp) receptor, to allow for increased absorption of anti-retroviral drugs (such as Amprenavir) 
into the cell system, which could lead to drug intoxication, but had no significant interaction 
with the drug itself (Katerere and Rewerts, 2011). 
 
1.4 PROBLEM STATEMENT 
Although there has been a recent boom in research on Sutherlandia, many shortcomings in 
scientific evidence on S. frutescens have appeared in the literature, both from a 
phytochemical, pharmacological, as well as from a medical point of view. These 
shortcomings have now been intensified by the discovery of variation in chemical 
composition between different plants from the same species. 
Field studies over a period of many years have shown that only two species should be 
recognised, along with several geographically separated subspecies (Moshe et al., 1998), this 
classification has not been implemented. In addition, many chemical variations are believed 
to occur, which could affect the variations in biological activity of various compounds 
present in these plants, as noted by Chinkwo (2005).  
Investigations into the medicinal properties of S. frutescens have tended to focus mainly on in 
vitro anti-cancer properties of extracts from this plant on different tumour cell lines 
(Chinkwo, 2005; Stander et al., 2007; Tai et al., 2004). Accordingly, very little 
documentation exists on in vivo studies of Sutherlandia extracts, their mechanism of action, 
or of the various compounds relating to these activities. Ngcobo (2008) has reported on the 
plant‟s immune-stimulating abilities on a T cell lymphoma cell line, H9, as well as on 
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Peripheral Blood Mononuclear Cells (PBMC), together with various cytokines produced 
during stimulation with certain Sutherlandia extracts. While studies by Ngcobo (2008) might 
suggest some kind of clinical evidence to support a direct anti-cancer effect of Sutherlandia 
extracts in some cancers, together with possible immune-stimulating/modulatory 
mechanisms, they have not been very well characterised and are subsequently not well 
understood. Furthermore, to date, no evidence of the anticancer and stimulated cytokine 
expression on a macrophage cell line and isolated macrophage cells has been investigated and 
its usefulness in fighting various diseases.  
In general, most biological assays on Sutherlandia extracts have tended to focus on the 
organic or traditional preparations of the plant material or commercial products (Van Wyk 
and Albrecht, 2008). No conclusive study of the compounds isolated and purified from the 
plant material, have been rigorously connected to biological activities. The mechanisms of 
action have not been extensively studied and it is not known how this highly appreciated 
medicinal plant functions or which compounds present in this plant are responsible for these 
actions. 
 
1.5 AIMS OF THE STUDY 
In view of the current lack of evidence, the objectives of this study were to investigate the 
chemical composition and biological activities of various preparations of one batch of plant 
material, as well as for the isolation and purification of compounds from these extracts.  
For the isolation and phytochemical characterisation of the extracts various solvents along 
with a variety of analytical techniques, spectral and chemical analysis were used; such as 
column chromatography, NMR spectroscopy (1D and 2D data), HPLC-MS as well as UPLC-
TOF-MS, before screening for biological activity.  
The biological screening assays were setup to determine the role S. frutescens plays in its 
anticancer and immune modulating activities by using a 3-cancer cell line panel (consisting 
of melanoma, breast and leukaemia cell lines) and a cytokine stimulation model (consisting 
of pro- and anti-inflammatory cytokines) in a leukaemia cell line. This was done to 
specifically link certain extracts and/or compounds that might be responsible for these 
activities, as a preliminary approach for further investigations. 
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As the study progressed, it also became necessary to investigate potential variations in the 
chemical profiles of various S. frutescens plant material, received from a commercial 
supplier. 
 
1.6 ORGANISATION OF THE DISSERTATION 
The dissertation was organised into two separate parts. Part One, which consists of Chapters 
2 to 5 (pages 19 to 66), describes the phytochemical investigations of plant extracts, while 
Part Two mainly focuses on the biological investigations on some of these extracts,   
comprising Chapters 6 to 8 (pages 67 to 107). 
Part 1 Phytochemical studies 
Chapter 2 contains the phytochemical techniques used for extraction procedures of the plant 
material, isolation of compounds, equipment used for this purpose and analysis techniques for 
chemotypes, extracts prepared and isolated compounds. 
Chapter 3 presents a detailed discussion of the phytochemical results of the various extract 
and fractions of S. frutescens, as well as the characterisation of the compounds isolated with 
their structures and identification procedures. 
 Chapter 4 contains a discussion of the differences and/or similarities found in extracts from 
six samples of plant material identified as Sutherlandia frutescens, obtained from a 
commercial supplier, that were analysed using HPLC-MS. 
Chapter 5 presents a conclusion from the observed phytochemical results from Chapters 3 
and 4.  
Part 2 Biological investigations 
Chapter 6 contains the materials and methods of the biological techniques used to determine 
the anti-cancer potential of selected extracts, cytokine release assay techniques, as well as 
instrumental descriptions used for these purposes.  
Chapter 7 contains a detailed account of a preliminary investigation into the bio-activities of 
selected extracts, fractions and compounds isolated from S. frutescens. Their anti-cancer 
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potential, stimulated release of cytokines by target cells, together with potential immune 
responses correlated with their chemical profiles, will be presented and discussed. 
In Chapter 8, the observed results (from Chapters 6 and 7) will be summarised with their 
concluding remarks. Future plans and suggestions regarding the investigation of medicinal 
values of extracts from S. frutescens and other medicinal plants will be given. 
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PART 1 
PHYTOCHEMICAL STUDIES 
CHAPTER 2 
MATERIALS AND METHODS 
 
Medicinal properties associated with plants can be verified by phytochemical and biological 
studies. The discovery of certain compounds present in plants could explain their use as 
traditional medicines against certain ailments. It has become an important aspect to study the 
plant from a phytochemical point of view in order to identify compounds that are related to 
its therapeutic properties that could be used to justify its use as a traditional medicine and for 
the discovery of new drugs for various diseases. The plant extracts, analysis of the chemical 
profiles of these preparations and the pharmacological assays play a very important role in 
drug discovery. Traditionally, a tea infusion of the leaves is used for the preparation of the 
plant material. In this study general extraction procedures were followed: some of which 
mimic the traditional preparations and other more scientifically accepted extraction 
procedures (i.e., various organic preparations) for standardisation and comparison of the 
activities present in the different preparations. Thus, this chapter detailed a discussion of the 
materials and methods used in the extraction of plant material, High Performance Liquid 
Chromatography-Mass Spectrometry (HPLC-MS) analysis and isolation and purification of 
compounds from the extracts. 
 
2.1 EXTRACT PREPARATIONS 
2.1.1 Materials 
All plant material (aerial parts) was obtained from a community-based project in Petrusburg 
in the Free State, South Africa (29° 6.774′ S; 25° 24.305′ E; 1249m above sea level). This 
project is fully funded by the Department of Science and Technology (DST) and 
implemented by the Council for Scientific and Industrial Research (CSIR), Enterprise 
Creation for Development Unit (ECD) in Pretoria. The seeds were supplied by a commercial-
based nursery in Wellington in the Western Cape, South Africa. Solvents (CP grade) that 
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were used in the laboratory were purchased from Merck and distilled before use. Solid phase 
extraction C-18 cartridges (Supelco 140ml PP tubes), Lipophilic Sephadex LH-20 and silica 
gel 60 were purchased from Sigma Aldrich. Distilled water (H2O) was used for all 
procedures.  
2.1.2 Plant Collection 
820 kg of fresh Sutherlandia aerial parts (leaves and stems) were received from Petrusburg in 
the Free State (seeds planted in September 2008, plants harvested in July 2009). Pilot scale 
drying was conducted in open air, which proved critical to bio-burden load. A twig 
containing a flower was sent to the South African National Biodiversity Institute (SANBI) for 
identification and was identified as Sutherlandia frutescens (L.) R. B.r. (SANBI Genspec 
number: 462 1) See Figure 2.1 below. 
A batch of 2.36 kg of the fresh stems and leaves were taken before drying and used for 
traditional preparations. This was placed in a fabric bag and stored in the cold room at 4 °C 
until processing. Once the remaining plant material (817.64 kg) had dried, the leaves and 
stems were separated and 6.5 kg of the dried leaves was taken and used for preparation of 
various organic and traditional extracts. Four kilograms of the dried leaves were used for a 
large scale production of a spray dried extract (seeds planted in September 2007, harvested in 
July 2008). Six samples of dry plant material (leaves) of S. frutescens were obtained from a 
commercial supplier for HPLC-MS profiling. 
 
21 
 
 
Figure 2.1 Photo of Sutherlandia frutescens (L.) R. Br. plant material received. 
 
2.1.3 Extraction procedures 
2.1.3.1 Fresh plant material extraction based on traditional procedures 
Fresh stems and leaves (2.36 kg) were used for the traditional extraction procedures. The 
stems (1.694 kg) and leaves (0.488 kg) were processed separately and boiled in 12.5L of 
distilled water (H2O) each, for 1 hour using a hot plate and steel extraction vessel, with 
occasional stirring. The suspension was then filtered through cheese cloth and collected in a 
bucket. The aqueous extracts were then freeze-dried and a powder subsequently obtained. 
This was stored in an airtight container in the cold room at 4 °C until processing. See Figure 
2.2 below for flow diagram of the extraction process and percentage yields of extracts with 
their sample numbers. The aqueous extract from the fresh leaves was labelled Extract A, 
while the aqueous extract from the fresh stems was labelled Extract B. 
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Figure 2.2 Flow diagrams for fresh and dry plant material processing showing sample 
numbers and percentage yield of each resulting extract. 
 
2.1.3.2 Dry plant material extraction based on organic and traditional 
procedures 
The dried leaves of S. frutescens (600 g) were separated into 3 x 200g each, labelled C, D, 
and E. Ethanol (EtOH; 1.6 L of 96% v/v) was added to 200 g of plant material. This was 
stirred, left overnight and then filtered and evaporated to give extract C. Extract D was 
obtained by boiling 200 g of plant material in 2.0L of distilled H2O for 1 hour with occasional 
stirring. This solution was filtered after it cooled down and freeze-dried. Extract E was 
obtained by adding a 1:1 dichloromethane: methanol (DCM: MeOH; 2.0 L) solution to 200 g 
of plant material, which was stirred overnight, filtered and evaporated. See Figure 2.2 above 
for flow diagram of the extraction procedures and percentage yields obtained. 
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2.1.3.2.1 Liquid-liquid partitioning of dried leaves 
A total of 1.7 kg of dried leaves was ground to a powder and extracted three times with 10.0L 
of methanol (MeOH) and stirred for 24 hours. Filtration of the extract was done with a 
vacuum pump before 12 g of anhydrous magnesium sulphate (MgSO4) was added and left for 
30 min. to remove water and filtered. The MeOH was evaporated (extract F). A portion 
(100g) of extract F was suspended in water and extracted sequentially with hexane, 
chloroform and n-butanol (each phase saturated with water and shaken for optimised 
extraction). All resulting filtrates were evaporated and labelled extract G, H, I and J 
(hexane, chloroform, butanol and water portions, respectively). See Figure 2.3 below for 
flow diagram of extraction procedure. 
 
 
Figure 2.3 Flow diagram for liquid-liquid partitioning of dry plant material (1.7 kg) 
showing sample numbers and percentage yields of resulting extracts. 
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2.1.3.2.2 Spray dried extract 
Extraction: Distilled water (60 L) was added to 4 kg of the dried leaves in an extraction 
vessel. This was then boiled for 1 hour. The extract was cooled by cooling the jacket of the 
extraction vessel. 
Filtration: A hydraulic press was used for filtration with a filter pad (PY07010 @ 185cm 
wide, WHATMAN) and two filter bags (FT557 @ 170cm wide, WHATMAN), one on the 
inside of the hydraulic press and one in the collection bucket. 
Spray drying: The Nitro Spray Dryer was operated with the following parameters: process 
gas 380 Kg/Hr; inlet temperature 180 °C; outlet temperature 88 °C; wall sweep temperature 
80 °C; pneumatic hammer 1 bar; wall sweep process gas 1 bar; atomizer 2600 rpm and filter 
clean pressure 5 bar. The spray dryer was run for 3 hours and 40 minutes. Pre-cleaning of the 
feed system was done. The spray-dried extract was collected, weighed and labeled extract K. 
2.1.3.2.3 Solid Phase Extraction (SPE) for extract C 
A C-18 (Supelco 140 ml PP tubes, Sigma Aldrich) cartridge was activated with 1:1 H2O: 
MeOH, 100 % MeOH and 100 % H2O. A 10 g sample of extract C was dissolved in 20 ml 
H2O and placed on the activated cartridge. This was run with 200 ml 100 % H2O, 160 ml 20 
% MeOH, 110 ml 40 % MeOH, 160 ml 60 % MeOH, 160 ml 80 % MeOH, 200 ml 100 % 
MeOH and 200 ml 100 % Acetonitrile (ACN). The resulting fractions were evaporated and 
freeze dried and combined to give fractions I to III. 
2.1.4 Immune-boosting standard  
Echinacea preparation 
Echinacea Premium Syrup (1 ml) from Medi Herb was used in this study as an immune-
boosting control and dried-off on the Genevac speedvac to remove the ethanol used in the 
formulation of the syrup. Each ml of syrup contains 1.5 mg of alkylamides (the active 
immune-boosting compounds). The tincture is made up of 60 % E. purpurea root (1:2 
dilution) and 40 % E. angustifolia root (1:2 dilution). The evaporated extract was given a 
sample code of Ech. 
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2.2 ISOLATION AND PURIFICATION OF COMPOUNDS  
In the following section of this chapter, details will be given of the various chromatographic 
techniques used to purify cycloartane and flavonol glycosides.  
2.2.1 Isolation and purification of cycloartane glycosides 
In this study, the butanol extract (17.2 g; extract I) was used to purify the cycloartane 
glycosides, which was subsequently subjected to silica gel column chromatography (particle 
size 0.063 - 0.2 mm), hereafter referred to as column a. The purification was done using a 
stepwise gradient mixture of chloroform (CHCl3): MeOH, starting from 100:0 until 70:30, as 
eluent to give an initial number of 24 fractions. From column a, five fractions (in the more 
non-polar region) were combined (6.33 g) and subjected to further silica gel column 
chromatographic purification, hereafter referred to as column b, and subsequently eluted 
using a stepwise gradient mixture of CHCl3: MeOH, starting from 95:5 until 75:25, to give 
another set of 20 fractions. Upon visual inspection of thin layer chromatography (TLC) 
plates, certain fractions were run on HPLC (using the method described below in section 2.3) 
to determine their purity. From these results, one non-polar fraction that eluted with 10 % 
MeOH, from column b, was found to be a fairly pure compound and was further crystallised, 
hereafter referred to as compound 4. Compound 4 was further analysed using the UPLC-
QTOF and Nuclear Magnetic Resonance spectroscopy (1D and 2D experiments) for its 
structure elucidation. Another set of more polar fractions - from column b - were combined 
(612.3 mg) and subjected to Sephadex (Lipophilic Sephadex LH-20) column 
chromatography, hereafter referred to as column c.  
Sephadex was pre-washed with 100 % H2O, 100 % MeOH and again with 100 % H2O. The 
washed Sephadex was then left overnight in H2O to allow swelling and then packed in a glass 
column. Column c was first eluted with H2O, followed by a stepwise gradient of increasing 
MeOH concentration. Small volumes (5 ml) were collected and evaporated on the Genevac. 
Collected test tubes were analysed with TLC and chemically similar samples were 
subsequently combined to give another set of 22 fractions. Two non-polar fractions - from 
column c (38.2 mg) - which were found to be fairly pure according to HPLC analysis, were 
then packed on a third short silica gel column for further purification, hereafter referred to as 
column d. Separation on this column was achieved with 100 ml of 100 % CHCl3, with 
increasing MeOH concentration in 1 % increments, every 100 ml, until 7 % MeOH was 
reached, followed by washing with 10 % MeOH. Test tube samples collected were 
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evaporated on the Genevac. Collected samples were analysed using TLC and chemically 
similar fractions were combined to give 3 resulting fractions. HPLC analysis was done on the 
second fraction (that eluted with 6 % MeOH) to determine its purity and it was found to be 
pure, hereafter referred to as compound 7. Compound 7 was further analysed using 600 
MHz Varian NMR (1D and 2D experiments) and UPLC-QTOF for structure elucidation. 
Finally, 7 of the non-polar fractions (37.0 mg) from column c, produced another set of 
fractions from a fourth silica gel column, hereafter referred to as column e. These fractions 
were purified using 100 ml of 100 % CHCl3, increasing the MeOH concentration by 1 % 
every 100 ml, up to 8 % MeOH and subsequently washed out with 10 % MeOH. TLC was 
run on the collected fractions and chemically similar ones were combined to give 4 fractions. 
From this, the second fraction (eluting with 5 % MeOH), from column e, hereafter referred to 
as fraction IV, was analysed using HPLC-MS to characterise the compounds present. A brief 
summary of the cycloartane glycosides purification process, incorporating the various runs 
and recombinations of columns a to e, are presented in Figure 2.4 below. 
 
Figure 2.4 Flow diagram of cycloartane glycosides column chromatography and 
resulting compounds and fractions. 
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2.2.2 Isolation and purification of flavonol glycosides 
For the isolation of the flavonol glycosides several column chromatographic techniques were 
employed, beginning with 10 g of extract K dissolved in 20 ml H2O and packed on a 50 g C-
18 cartridge (the cartridge was first activated as explained above just with a 1:1 dilution of 
H2O: MeOH, 100% MeOH and 100 % H2O, sequentially). The extract was packed on the C-
18 cartridge and eluted with 250 ml of 100 % H2O, 160 ml 20 % MeOH, 110 ml 40 % 
MeOH, 160 ml 60 % MeOH, 160 ml 80 % MeOH, 200 ml 100 % MeOH and washed with 
100 ml 1:1 MeOH: ACN and 100 ml 100 % ACN. This was repeated three times with the 
same quantities and extract. All resulting fractions were freeze dried, evaporated and 
combined. Flavonoid detection was done on the resulting fractions from column f using 1 g 
of ferric (iii) chloride hexahydrate (FeCl3.6H2O) dissolved in 1 ml of H2O and 1 ml of each 
fraction. A colour change from yellow to blue-green confirmed the presence of flavonoids in 
one of the polar fractions (Bf) only, which was taken for further purification.  
Thereafter a Discovery DPA-6S (60 ml Tube; 5 g) polyamide cartridge was activated with 
100 % MeOH and 30 % MeOH. This polar fraction (500 mg) was dissolved in 3:7 MeOH: 
H2O and packed on the activated cartridge, hereafter referred to as column g. Fraction Bf was 
chromatographed employing a solvent system of increasing MeOH concentration starting 
from 30 % until 70 %. The column was then washed with 95.5: 0.5 MeOH: ammonia (NH3) 
and 85:15 dimethylformamide: H2O. Each solvent system ratio was collected separately in 
vials labelled and evaporated to give 7 fractions. Fraction 4 (70 mg), from column g, was 
subsequently packed on a silica gel column and eluted with 90:10:1 (CHCl3:MeOH:Formic 
acid); 85:15:1 and washed with 100 % MeOH, hereafter referred to as column h. TLC 
analyses on the collected test tubes, from column h were conducted, and chemically similar 
test tubes were combined to give 8 fractions. From column h, fractions Bh and Dh, hereafter 
referred to as fractions V and VI, were used for screening of flavonoid activity. A brief 
summary of the purification of the flavonol glycosides is shown in Figure 2.5 below. 
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 Figure 2.5 Flow diagram of flavonoid column chromatography and resulting fractions. 
 
2.3 HIGH PERFORMANCE LIQUID CHROMATOGRAPHY AND MASS 
SPECTROMETRY (HPLC-MS) 
The various extracts, fractions and compounds were then analysed using a High Performance 
Liquid Chromatography-Single Quadrupole Detector-Mass Spectrometry (HPLC-SQD-MS) 
instrument to determine their chemical profiles. Ultra Performance Liquid Chromatography-
Quadrupole Time of Flight-Mass Spectrometry (UPLC-QTOF-MS) was used for structure 
elucidation and accurate mass determination of the isolated compounds. HPLC and UPLC are 
highly developed powerful analytical techniques with a wide range of variations available 
mainly used as preparative tools and to obtain chemical fingerprints of plant material (Holme 
and Peck, 1998), while MS and QTOF, coupled to these techniques, allow for faster analysis 
time, being used for the identification and structure elucidation of the components therein. In 
the drug development process, MS has been used for lead compound discovery, structural 
analysis, synthetic development, combinatorial chemistry, pharmacokinetics and drug 
metabolism (Pavia et al., 2009). QTOF allows for a more accurate mass analysis, which is 
based on principle that the velocities of two ions vary based on the mass of the two ions 
29 
(Pavia et al., 2009). This gives us indication of the quantity of compounds present, and 
together with their molecular masses, allows identification of intrinsic differences and 
similarities between compounds present in the plant extracts. 
2.3.1 Sample preparation 
Commercial samples: For each sample approximately 2 g of the dried, ground leaves 
was weighed out into a volumetric flask and 5 ml of HPLC-grade methanol was then added. 
This was then put in the ultrasonic bath for 30 minutes, transferred to a vial and centrifuged 
for 10 min. at 2500 rpm. The supernatant was then removed, with the whole process being 
twice repeated. 
Extracts and fractions: For each extract and fraction, approximately 25 mg was 
weighed out into a vial and 2 ml of HPLC-grade solvent (methanol, acetonitrile or water 
depending on the solubility of the sample) was added. This mixture was then put in an 
ultrasonic bath for 10 minutes and filtered through Acrodisc GHP syringe filters, before being 
placed into 2 ml HPLC vials. 
Compounds: For each compound isolated approximately 1 mg was weighed out into 
a vial and 2 ml of HPLC-grade solvent was added (solvent choice depended on compound 
solubility). This mixture was then put in an ultrasonic bath for 10 minutes and filtered 
through a 0.2 μm GHP filter membrane filter, before being injected into HPLC vials using a 
Norm-jet Luer Lock syringe. These compounds were also run on UPLC-QTOF to obtain the 
accurate mass of each. 
2.3.2 HPLC-MS analysis 
The various samples were analysed using a WATERS 2695 HPLC separation module. Two 
Atlantis T3 columns (10 x 250 mm, 5 µ particle size) connected in series, were used for the 
separation. UV-VIS detection was done on a WATERS PDA scanning from 200 – 600 nm. 
The mobile phase used was 0.1 % (v/v) formic acid in water (A), methanol (B) and 
acetonitrile (C). The ratio of mobile phase components that were optimised for the extracts 
prepared (see section 2.2.1) is given in the Table 2.1 below. Additionally, mass spectrometry 
detection was performed using a WATERS SQD scanning from 100 – 1200 m/z with polarity 
(+/-) switching with a scan time of 0.20 seconds. The operating conditions in the ESI source 
were as follows: source temperature, 150 °C; desolvation temperature, 450 °C; capillary 
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voltage, 3.00 kV; cone voltage, 30.0 V. Gas flow (N2): desolvation, 800 L/hr; cone gas, 10 
L/hr. 
Table 2.1 The Gradient timetable for the HPLC-SQD method. 
Time (min) Flow rate 
(ml/min) 
% A 
FA H2O 
% B 
MeOH 
% C 
ACN 
0.00 0.3 95.0 5.0 0.0 
4.00 0.3 95.0 5.0 0.0 
5.00 0.3 75.0 25.0 0.0 
27.00 0.3 55.0 45.0 0.0 
30.00 0.3 42.0 58.0 0.0 
70.00 0.3 22.0 78.0 0.0 
80.00 0.3 12.0 88.0 0.0 
85.00 0.3 12.0 88.0 0.0 
90.00 0.3 0.0 100.0 0.0 
100.00 0.3 0.0 100.0 0.0 
107.00 0.3 0.0 0.0 100.0 
113.00 0.3 0.0 0.0 100.0 
115.00 0.3 95.0 5.0 0.0 
 
2.4 GENERAL EQUIPMENT USED FOR COMPOUND AND EXTRACT ANALYSIS 
HPLC analysis on the extracts and fractions was done on a WATERS 2695 HPLC separation 
module with a PDA and a SQD, with the help of Nial Harding. Two Atlantis T3 columns (10 
x 250 mm, particle size: 5 µ) were used. 
For structure elucidation of the compounds, NMR spectroscopy was performed using a 600 
MHz Varian NMR, using deuterated solvents depending on the solubility of the samples 
(pyridine-d5 or methanol-d4). The duration of the experiments that were run, depended on the 
purity and quantity of the samples. All samples were run at a set temperature of 25 °C. 
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Accurate mass analysis was performed on a WATERS Synapt G1 UPLC-TOF-MS system by 
Paul Steenkamp. Two column types were used namely, WATERS Acquity CSH C18 (150 x 
2.1 mm, particle size: 1.7 µ) for the apolar compounds and WATERS Acquity HSS T3 (150 x 
2.1 mm, particle size: 1.8 µ) for the more polar compounds.  
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PART 1 CONT. 
CHAPTER 3 
RESULTS AND DISCUSSION 
OF EXTRACTS AND COMPOUNDS 
 
HPLC-MS is an analytical chemistry technique that uses the physical separation capabilities 
of liquid chromatography and the mass analysis capabilities of mass spectrometry. It is used 
for the specific detection, potential identification, stability and purity studies of chemicals 
present in a complex mixture. Various scientific studies have found, that determining the 
chemical profile of plant extracts, helped in identifying some of the chemical components 
present and also provided guidance for further investigations in pharmacological activity in 
support of traditional uses. Nuclear Magnetic Resonance (NMR) spectroscopy and 
Quadrupole Time-of-Flight (QTOF) have proved to be useful techniques for the structural 
elucidation of compounds isolated from plant material. NMR exploits the magnetic properties 
of nuclei present in the atoms, which results in a characteristic spectrum that can be used for 
determining the structure of the isolated compounds. Various 1D and 2D experiments were 
used (such as proton - H
1
, carbon - C
13
, Heteronuclear Multiple Bond Correlation - HMBC, 
Heteronuclear Single Quantum Coherence - HSQC, Correlation SpectroscopY - COSY and 
Distortionless Enhancement by Polarisation Transfer - DEPT) to determine the proton to 
carbon relation and the chemical environment they are in for structure elucidation (Silverstein 
et al., 2005).  
QTOF provides a measurement of the accurate mass of the compound/s under investigation 
and the resulting fragmentation pattern which was used, in conjunction with the NMR data, 
for structure elucidation. QTOF is a technique used to determine the mass of the compound 
under investigation using the principle that smaller (lighter) ions will travel faster through a 
flight tube than larger (heavier) ions. The velocity of an ion depends on its mass-to-charge 
ratio. The velocity that an ion obtains in the TOF analyser is therefore used to determine the 
mass of the ion and is a more accurate estimate (Silverstein et al., 2005; Pavia et al., 2009). 
In this chapter, the chemical profiles of the extracts made, together with fractions obtained, 
along with characterisation of the isolated compounds, will be presented. The extracts and 
fractions were analysed using the WATERS HPLC-PDA-SQD system (HPLC), while the 
33 
compounds were analysed on the WATERS Synapt G1 UPLC-TOF-MS system (UPLC) for 
accurate mass detection. 
3.1 CHEMICAL PROFILES OF EXTRACTS 
The HPLC chromatograms of the various extracts, fractions and compounds can be found in 
Appendix 2. Selected chromatograms however, have been included in this portion of the 
Dissertation, and show the chemical profiles of some of the extracts made from the leaves of 
S. frutescens (see Chapter 2, section 2.1.3, page 21). The chemical profile of extract C 
(ethanol extract) is shown below (see also Appendix Figure 2.1, page 122). In the extracts, 
the major cycloartane glycoside found in S. frutescens, compound 5, was found to elute at 
43.51 minutes in ESI negative mode. The other compounds isolated were found to elute at 
57.24 and 59.25 minutes in ESI negative mode for compound 7 and 4, respectively.  
 
 
Figure 3.1 The ESI
+
, ESI
-
 and UV chromatograms for extract C with the regions and 
compounds 4, 5 and 7 labelled in negative mode. UV-VIS was detected in the range 
from 200 to 600 nm. 
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From Figure 3.1 above, it can be seen that the polar compounds are found to elute from 10 to 
30 minutes, with a characteristic UV pattern. As the less polar region of the extract starts to 
elute (from 40 to 90 minutes), there is a great decline in UV activity, reflecting very little, or 
lack of aromatic rings and/or conjugated double bonds in the less polar compounds present in 
this region. As such, S. frutescens can be regarded as being one of the very few herbal plants 
whose extracts cannot be successfully separated or chemically profiled just on the basis of 
UV activity. This is possibly due to the presence of a complex mixture of compounds with 
little or no UV activity, as can be seen in the ESI
+
, ESI
-
 and UV chromatograms above. The 
cycloartane glycosidic compounds are found to elute from 40 to 60 minutes and display very 
low UV activity. The very non-polar compounds (from 80 to 90 minutes) have not been 
identified from Sutherlandia as of yet, and also show a lack in UV absorbing abilities. The 
flavonol glycosides are more polar in nature and therefore are found to elute from 20 to 30 
minutes, with characteristic UV profiles, showing the presence of more aromatic rings and 
conjugated double bonds found in these compounds. 
For the purpose of comparison of the chemical profiles from the various extracts made from 
S. frutescens, specific focus will be placed on the ESI
-
 and ESI
+
 chromatograms (depending 
on which show better ionisation of the compounds) due to a lack of UV activity. The ESI
-
 
chromatograms of the aqueous preparations of the fresh leaves and stems, namely extracts A 
and B respectively, together with the spray dried aqueous extract of the dried leaves (extract 
K), are discussed below. Corresponding chromatograms can be found in Appendix 2 
(Appendix Figure 2.2, page 123). 
From these chromatograms, the presence of more polar compounds, eluting from 15 to 27 
minutes and majority of the triterpenoid type compounds eluting from 40 to 60 minutes can 
clearly be seen. It is apparent that there is very little variation in the chromatographic profiles 
of the polar compounds. However, variations in the triterpenoid region of the different 
aqueous preparations were observed. This result might be due to their different solubility 
characteristics and could also be attributed to the natural drying process in the initial 
preparation of plant material that could have resulted in the degradation of some of the 
unstable triterpenoid compounds, thereby causing a variation. The difference in the 
triterpenoid region might also be due to the different drying processes used to absorb the 
water from the extracts after filtration. For example, freeze drying was employed on the 
aqueous extracts from the fresh plant material, while spray drying was used on the aqueous 
extracts from the dry plant material. The freeze drying process might be more suitable for 
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controlling instability of these thermally labile compounds, where low temperatures were 
used to absorb the water, while the spray drying process used high temperatures (ranging 
from 60 to 160 °C) to evaporate the water, which might have further caused the degradation 
of the compounds present in the triterpenoid region of the chromatogram.  
In addition, the aqueous extract of the fresh stems contained a lower concentration of the 
compounds when compared to the aqueous extract of the fresh leaves. One can therefore 
conclude that the stems of Sutherlandia do not contain many of the compounds found in 
other parts of the plant and are probably in rapid transit from the roots to the leaves via the 
stems. As such, the compounds are probably stored in the leaves, confirming the presence of 
a higher concentration of the compounds which were found in extracts from the leaf material. 
The next part of the results and discussion will be around the chemical profiles of the 
methanol extract and resulting phases from it (extracts F, G, H, I and J, see Appendix Figure 
2.3, page 124). 
Extract I contained the majority of the compounds found in the triterpenoid region. For this 
reason, most of the purification was done on this portion, to isolate the triterpenoids found in 
Sutherlandia species. The hexane soluble part of the methanol extract (extract G) mostly 
contained the fatty acids and other non-polar compounds, due to their solubility affinities. 
The chloroform soluble portion of the methanol extract (extract H) dissolved some 
compounds eluting in the triterpenoid region with very little UV activity. Extract I contained 
mainly the triterpenoid region and some of the less polar compounds that were not soluble in 
the water portion (extract J). Extract J contained the rest of the compounds present from 
extract F that were not soluble in any of the other phases. The very polar compounds 
remained in high concentrations in this extract. Extracts C, D and E‟s (ethanol, water and 
DCM:MeOH extracts, respectively) ESI
- 
chromatograms of the extracts of the dried leaves 
from S. frutescens are discussed below (see Appendix Figure 2.4, page 125). 
The ethanol extract (extract C) was fairly similar to the butanol extract (extract I) with a 
high concentration of compounds in the triterpenoid region and a lower concentration in the 
polar region. In general, it was found that a low concentration of the flavonoids dissolved in 
the ethanol extract. The aqueous extract of the dried leaf material (extract D) contained a 
higher concentration of the polar compounds (from 15.00 to 30.00 minutes), while the 1:1 
DCM:MeOH extract (extract E) displayed a higher concentration of compounds found in the 
triterpenoid region (from 40.00 to 60.00 minutes) when compared to the other extracts. 
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3.2 CHEMICAL PROFILES OF FRACTIONS 
The following section presents the chemical profiles of each of the resulting fractions I to VI 
obtained from the further purification of the extracts above (see Chapter 2, sections 2.1.3 and 
2.2, pages 21 and 25). The chromatograms of each fraction can be found in Appendix 3 
(page 126 to 131). Extract C was further purified (using SPE, Chapter 2 section 2.1.3.2) into 
three fractions namely, fractions I, II and III, while the resulting triterpenoid fraction 
(fraction IV) was purified from extract I and fractions V and VI (the flavonoid rich 
fractions) were purified from extract K. These fractions were discussed based on their ESI
+
 
chromatograms due to better ionisation of compounds than in negative mode. 
Fraction I was found to contain more polar compounds, while fraction II contained mainly 
the glycosidic triterpenoid type compounds that were more polar in nature due to the presence 
of a sugar moiety attached to the structure. Fraction III contained the non-polar compounds. 
Fraction IV contained compounds 4 and 7 (identified using retention time and mass spectral 
data) in very minor quantities, while compound 5 was not found to be present in this 
fraction. The major peaks eluting in this fraction have similar fragmentation patterns 
characteristic of the cycloartane glycosides isolated from S. frutescens (compounds 4 to 7). 
There are still many more of these compounds to be isolated from the plant material and 
further investigations need to be done on different purification techniques, thereby making it 
easier to achieve higher yields of the compounds. Two purified fractions, which contained the 
characteristic flavonol glycosides isolated from S. frutescens, were obtained. The compounds 
were not isolated in a pure form due to their low quantities as well as their inclination to 
degrade. The compounds present in the chromatograms showed a mass fragmentation and 
UV pattern characteristic of compounds 8 to 11. For a full chromatogram of fraction V and 
VI see Appendix Figure 3.2 (page 127). In fraction V, the peaks eluting at 24.73 and 25.51 
minutes displayed similar mass fragmentation and UV spectra to that of compounds 10 and 
11, whereas in fraction VI the peaks eluting at 21.21 and 22.23 minutes displayed similar 
mass fragmentation and UV spectra to that of compounds 8 and 9 (Fu et al., 2010; Avula et 
al., 2010). These results are therefore indicative that these compounds could possibly be 
compounds 8 to 11 present in the fractions, however this cannot be confirmed based on mass 
spectral data alone, due to the closely related structures (mass spectral and UV data can be 
found in Appendix Figures 3.3 to 3.6, pages 128 to 130). Further investigations on different 
purification techniques should be done, in order to obtain more compounds from 
Sutherlandia in high enough quantities for more detailed NMR analysis. There are many 
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other peaks found in the chromatograms that exhibit similar fragmentation patterns, but with 
different maximum UV absorptions, that are suggestive of the presence of closely related 
flavonol glycosides. Further work needs to be done to isolate these compounds in purer and 
higher concentrations so that better comparisons can be made with commercial standards as 
well. Appendix Figures 3.5 and 3.6 show the UV absorption spectra of the two peaks in 
fractions V and VI which could correspond to compounds 10 and/ or 11 in fraction V and 8 
and/ or 9 in fraction VI. 
Appendix Figure 3.5 shows the UV spectra from fraction V with a similar UV absorption 
pattern to that of compounds 10 or 11 (Avula et al., 2010) suggesting that this compound 
could possibly be that of compound 10 or 11 i.e. sutherlandin C or D. The mass spectral data 
(shown in Appendix Figure 3.3, page 128) corresponds to that found in the study done by 
Avula et al. (2010). However, the structure cannot be confirmed, due to the lack of NMR 
supporting data, because of insufficient quantities for NMR analysis. The UV data of peaks 
found in fraction VI can be found in Appendix Figure 3.6. The two peaks that elute at 21.14 
and 22.16 minutes in fraction VI, shows a comparable UV absorbing pattern to that found 
for compounds 8 and 9 by Avula et al. (2010), suggesting that these compounds could 
possibly be that of compounds 8 or 9, namely - sutherlandin A or B, present in the fractions. 
The mass spectral data (shown in Appendix Figure 3.4, page 129) corresponds to that found 
in the study done by Avula et al. (2010). However, the structures cannot be confirmed due to 
the lack of NMR supporting data. Further purification of the compounds is needed to confirm 
the structure with NMR analysis. Figure 3.2 below shows the structures of the flavonol 
glycosides (compounds 8 to 11) that have been previously isolated from S. frutescens. 
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Figure 3.2 Structures of compounds 8 (A), 9 (B), 10 (C) and 11 (D) from Fu et al., 2010 
and Avula et al., 2010. 
 
In order to provide some reasonable explanation as to the order of elution of the four 
flavonoids, further analysis was done. Various UPLC-MS and UPLC-MS-MS experiments 
were performed and it was shown that the first pair - the di-hydroxy flavonoids (compounds 
8 and 9 - quercetin 3-O-diglycosides) - was found to elute first (m/z 740.1) and the mono-
hydroxy flavonoid pair (compounds 10 and 11 - kaempferol 3-O-diglycosides) being less 
hydrophilic eluted after (m/z 725.1). Further attempts to determine which flavonoid elutes 
first from the pairs were done [i.e., from the di-hydroxy pair - compound 8 or 9 - which 
would elute first; the one containing the 6-membered sugar (pyranose) attachment (8 and 10) 
or the one with the 5-membered sugar (furanose) attachment (9 and 11)]. A 3D structure 
evaluation was performed. The structures were drawn in ChemSketch 12
2
 and optimised for 
3D viewing. All the settings for 3D optimisation were default settings supplied by the 
software. 
                                                          
2
 Software downloaded from ACD labs (Advanced Chemistry Development, Inc.), which is freely available at 
<http://www.acdlabs.com/resources/freeware/chemsketch/>. 
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Figure 3.3 3D representations of compounds 8 to 11 showing the sugar regions and the 
space occupied by each. This figure was originated using 3D ChemSketch software 
version 12.0. 
 
From the structure representations of the di-hydroxy flavonoid pair (compounds 8 and 9) it 
was shown that the 5-membered sugar region (of compound 9) occupied more space thus 
encountering a higher level of interactions with the stationary phase, resulting in a longer 
elution time. The same occurs for the mono-hydroxy flavonoid pair (compounds 10 and 11). 
Compound 11 occupies more space and therefore allowing more interaction with the 
stationary phase to take place thus eluting at a later time. From these observations, the 
proposed order of elution would thus be as follows: compound 8, 9, 10 and 11 (sutherlandin 
A, B, C and D respectively). This order of elution is in agreement with the published 
information from Avula and co-workers (2010). Appendix Figures 3.7 and 3.8 (page 131) 
provide the proposed structure analysis and order of elution as investigated on the UPLC 
system. 
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3.3 CHARACTERISATION OF COMPOUNDS 
Natural compounds have been used extensively in the treatment of many infections and are of 
interest to researchers both in their natural forms and as templates for synthetic modification. 
Natural compounds currently used in medicine exhibit a very wide chemical diversity, and 
together with their analogues and several other natural products, they demonstrate the 
importance of compounds from natural sources in modern drug discovery efforts.  
Scientific studies have shown triterpenoids to be potential anti-inflammatory and anti-cancer 
agents (Yadav et al., 2010). A structure-activity relationship study by Kikuchi et al. (2007) 
has shown that the most powerful inhibitory effects were found in cycloartanes with 
hydroxylation at C-24 and a 3-oxo group in an in vivo mouse skin carcinogenesis test. Such a 
configuration was found in one of the cycloartane glycosides from Sutherlandia namely, 
compound 5 (Van Wyk and Albrecht, 2008). 
At least 56 different triterpene glycosides have been detected in Sutherlandia (Van Wyk and 
Albrecht, 2008). The mixture of cycloartane-type triterpenoid glycosides varies 
geographically in South Africa (Van Wyk and Albrecht, 2008). A study done by Fu et al. 
(2008) found four cycloartane-type triperpenoids (see chapter 1 compounds 4 to 7, page 11) 
that are said to have a bitter tonic activity that stimulates appetite and may contribute to the 
adaptogenic and immune-boosting effects of Sutherlandia. Two of these compounds are also 
known as SU1 (compound 5) and SU2 (compound 4) (Van Wyk and Gericke, 2000). 
Sutherlandia leaves are also known to contain at least six flavonoids (Moshe, 1998). A study 
done by Fu et al. (2010) identified four of these to be flavonol glycosides named sutherlandin 
A, B, C and D (see Chapter 1, Figure 1.7 compounds 8 to 11, page 12). Flavonoids are said 
to have anti-oxidant activity and help to eliminate mutagen and carcinogens - which are of 
value in cancer prevention (Tai et al., 2004). They exert their anti-oxidant effects by 
neutralizing or by chelating different types of oxidizing radicals which includes the 
superoxide and hydroxyl radicals (Baghat, www.scribd.com). 
Following the procedures discussed in Chapter 2 section 2.3 (page 28), the n-butanol phase 
(extract I) from the methanol extract was used for isolation of triterpenoid compounds as this 
phase was found to mainly contain types of compounds associated with immune-boosting 
activities. The spray dried water extract (extract K) was used to isolate the flavononol 
glycosidic compounds, which were present in high concentrations. This section will focus on 
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the compounds which were isolated and subsequently characterised, using NMR 
spectroscopy and UPLC-QTOF spectrometry.  
3.3.1 Compound 5 standard 
Compound 5 is said to be a major triterpene found in commercial Sutherlandia material; it is 
also said to be the active compound for the anti-cancer properties related to Sutherlandia 
(Van Wyk and Gericke, 2000). A standard of the compound was kindly supplied by Prof. C. 
Albrecht
3
. This was used for NMR and spectroscopic analysis for comparison purposes only 
and was not isolated by the author. The structure was corroborated on a 600 MHz Varian 
NMR using deuterated pyridine (d-pyr) and a WATERS Synapt G1 UPLC-TOF-MS 
supported initial findings on the WATERS HPLC-PDA-SQD system. Compound 5 was not 
visible on a Thin Layer Chromatographic (TLC) plate, under either long (360 nm) or short 
(254 nm) wavelength UV light. However, after spraying the plate with vanillin reagent and 
heating it at 100 °C for a few minutes, the compound became visible as a purple spot with an 
Rf of 0.1 (solvent system 9:1:0.1 chloroform: methanol: formic acid).  
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Figure 3.4 Structure of compound 5. 
 
Following the HPLC method as discussed in Chapter 2 section 2.3.2 (page 29), the standard 
was analysed to determine its retention time and profile. The chromatogram from the UPLC-
                                                          
3
 Prof. C. Albrecht. Head of Research. Cancer Association of South Africa, Durbanville. 
calbrecht@cansa.org.za 
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TOF-MS system for the standard of compound 5 can be found in Appendix 4 (Appendix 
Figure 4.1, page 132). In this chromatogram, compound 5 was found to elute at 1.73 minutes 
in ESI negative mode. Further NMR analysis was carried out on this compound to confirm its 
structure. The Table below shows NMR data for compound 5 in pyridine-d5 (d-pyr).  
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Table 3.1 
13
C and 
1
H (600 MHz) data for compound 5 in pyridine-d5 (d-pyr) being 
compared to literature. 
Position
δC mult. δH (J  = Hz) δC mult. δH (J  = Hz)
1 210.7 210.7
2a 49 2.81 dd (13.7, 4.3) a 48.8 2.81 dd (13.6, 4.4)  
2b 3.23 dd (13.7; 4.3) b 3.23 dd (13.8, 4.2)  
3 78.7 4.04 m 78.5 4.03
4 40.1 39.9
5 38.9 2.93 dd (13.8, 3.4) 38.7 2.90 dd (13.4, 3.4) 
6 31.7 1.65 m; 2.19 m 31.5 1.66; 2.17
7 68.5 4.04 m 68.4 3.97
8 51.8 2.43 d (4.2) 51.5 2.43 d (4.0) 
9 28.8 28.7
10 39.5 39.2
11a 29.4 2.01 m 29.2 1.99
11b 2.38 br d (14.1) 2.37 dd (12.8, 2.8) 
12 33.8 1.55 m; 1.88 m 33.6 1.54; 1.84
13 46 45.9
14 50.2 50.1
15 34.7 1.55 m; 1.88 m 34.5 1.55, 1.86 
16 28.6 1.35 m; 1.88 m 28.4 1.36 t (14.0), 1.84 
17 52.6 1.65 m 52.4 1.6
18 16.2 1.0 s 16 0.99 s 
19a 24.6 0.86 d (4.7) 24.4 0.86 d (4.4) 
19b 1.65 m 1.60 d (4.0) 
20 37.5 1.47 m 37.4 1.46
21 19.4 0.96 d (6.5) 19.3 0.95 d (6.0) 
22 35.1 1.14 m; 2.19 m 34.9 1.12; 2.17
23 29.7 1.47 m; 1.88 m 29.5 1.46; 1.83
24 78.9 3.85 br d (7.0) 78.7 3.84 br d (9.2) 
25 81.4 81.3
26 21.7 1.58 s 21.6 1.57 s 
27 24.8 1.55 s 24.6 1.54 s 
28 25.8 1.27 s 25.6 1.26 s 
29 21.9 1.05 s 21.7 1.04 s 
30 19.1 1.10 s 18.9 1.09 s 
1' 99.2 5.25 br s 99 5.24 d (7.6) 
2' 75.9 4.04 m 75.7 4.04 t (7.4) 
3' 79.2 4.28 m 79 4.28
4' 72.2 4.28 m 72 4.22
5' 78.6 4.04 m 78.4 4.03
6'a 63.2 4.38 m 63 4.34 dd (11.6, 5.2) 
6'b 4.56 br d (11.7) 4.54 br d (10.8) 
Literature *Compound 5 
 
* Literature data from Fu et al., 2008. 
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NMR data of the compound 5 (see Table 3.1 above) revealed thirty six resonance signals in 
the 
13
C spectrum, confirming that the compound has a triterpenoid glycoside skeleton. 
Structural elucidation of triterpenoids is challenging, especially to characterise the complex 
saturated alkyl region. In the 
13C spectrum, there is evidence for a carbonyl function (δC 
210.7 ppm), a cyclopropane (δC 28.8, 39.5 and 24.6 ppm), three oxygen-containing methine 
groups (δC 68.5, 78.7 and 78.9 ppm) and the presence of a sugar (δC 63.2, 72.2, 75.9, 78.6, 
79.2 and 99.2 ppm). 
From the proton spectrum, the anomeric proton from the sugar is seen at δH 5.25 ppm as a 
broad singlet, while the other five protons from the sugar are found at δH 4.28, 4.28 4.08, 4.38 
and 4.56 ppm. Six singlet resonances show the confirmation of the six methyl groups 
attached to quaternary carbons (δH 1.58, 1.55, 1.27 1.05, 1.10 and 1.1 ppm). One doublet 
resonance at δH 0.95 ppm shows the presence of another methyl group attached to a methine 
carbon. The 
13
C and 
1
H spectra of compound 5 can be found in Appendix 5, pages 139 and 
140. 
High resolution Time-of-Flight Mass Spectroscopy (HRTOFMS) can be used to confirm the 
molecular mass of the compound. The spectrum below (Figure 3.5) shows the mass spectrum 
of compound 5 with its fragmentation pattern that was obtained from UPLC-QTOF analysis. 
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Figure 3.5 HRTOFMS (ESI
-
 and ESI
+
) spectra for compound 5. 
 
The mass spectrum from HRTOFMS (Figure 3.5 also found in Appendix Figure 4.2, page 
133) is similar to that found in literature (Fu et al., 2008) and shows m/z 675.4003 (C36H60O10 
+ Na)
+
 in ESI
+
 mode, m/z 697.4166 (C36H60O10 + HCOOH)
-
 as well as m/z 633.3931 
(C36H60O10 - H2O)
- 
in ESI
-
 mode
 
thereby confirming the accurate mass of the compound 
652.4073 (C36H60O10). A gas phase dimer is shown to be formed at m/z 1322.7495 (2M + 
Na)
+
 in ESI
+
 mode. The compound has a λmax of 219 nm (see Appendix Figure 4.10, page 
138). An elemental composition analysis was done on the m/z 697.4166 which gave the 
formula C37H61O12 (which fits the formula M + HCOO
-
) with an i-FIT value of 0.0 (a value 
closer to zero shows a perfect fit), a mass error of 0.3 (value should be < 5) and a calculated 
DBE value of 7 (double bond equivalents and ring structures which fit the structure and 
double bond count of the compound and possible adducts calculated on the molecular 
formula C36H60O10). All the above mentioned data confirmed the structure of the standard 
obtained to be that of compound 5 (3R,7S,24S,25S-tetrahydroxycycloartan-1-one 25-O-β-D-
glucopyranoside). Once the compound‟s structure and its purity have been confirmed, it can 
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then be tested in various biological assays to determine its activity. The graphs for the activity 
of compound 5 in the cancer cells and cytokine expression assays will be presented in 
Chapter 7, section 7.1.3.4 and 7.2 (page 84 to 87). 
3.3.2 Characterisation of compound 4 
Compound 4 was isolated from the n-butanol soluble portion (extract I) of the methanol 
extract of the leaves of S. frutescens by column chromatography on silica gel and was 
crystallised using methanol (see Chapter 2 section 2.2.1, page 25). Compound 4 was not 
visible on a TLC plate under either long (360 nm) or short (254 nm) wavelength UV light. 
However, after spraying the plate with vanillin reagent and heating it at 100 °C for a few 
minutes, the compound showed up as a purple spot with an Rf of 0.2 (solvent system 9:1:0.1 
chloroform: methanol: formic acid). Only a 0.006 % yield was obtained from the 17.2 g of 
extract I that was used, whereas a 0.2 % yield was obtained from 29.75 g of the same extract 
from the study done by Fu et al., 2008.  
Compound 4 was analysed using UPLC to determine its retention time and chemical profile. 
The resulting chromatogram can be found in Appendix 4 (Appendix Figure 4.3, page 134). 
Compound 4 displayed a retention time of 2.89 and 2.91 minutes in ESI negative and 
positive modes, respectively. The resulting chromatogram confirmed the purity of compound 
4, which was subsequently subjected to NMR analysis, to determine the structure of the 
compound. Table 3.2 below shows the NMR data for compound 4 in methanol-d4 (CD3OD), 
which was compared to that found in literature to determine its structure (Fu et al., 2008). 
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Table 3.2 
13
C data (600 MHz) for compound 4 in methanol-d4 (CD3OD) being compared 
to literature in d-pyr. 
Compound 4 Literature *
Position δc mult. δc mult.
1 71.8 72
2 31.5 31.8
3 77.8 77
4 38.3 37.7
5 46.7 46.1
6 31.3 30.9
7 77.1 75.8
8 53.9 53.1
9 135.8 135.9
10 85.3 84.8
11 122.4 121.1
12 38 37.6
13 46.5 45.7
14 46.2 45.4
15 34.8 34.4
16 29 28.8
17 51.7 51
18 15.6 15.5
19 42.8 42.8
20 37.2 37.2
21 18.9 19.2
22 35 35
23 29.3 29.6
24 78 78.7
25 81.6 81.3
26 22.8 21.7
27 23.9 24.6
28 27 27.4
29 23.1 24
30 20.3 20
1' 98.1 99
2' 75.5 75.7
3' 78.4 79
4' 72.8 72.1
5' 77.9 78.6
6' 62.9 63.1  
* Literature data from Fu et al., 2008. 
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From the NMR data in Table 3.2 the first dominant feature of compound 4 is that it lacks a 
carbonyl carbon at position 1 (as seen in the structure of compound 5 at δC 213 ppm); this is 
substituted by the presence of an oxygen-containing methine group (δC 71.8 ppm), thus 
exhibiting three oxygen-containing methine groups (δC 71.8, 77.8 and 78 ppm), which is also 
found in literature of compound 4 (at δC 72, 77 and 78.7 ppm). The next dominant feature is 
the absence of the cyclopropane structure, which is substituted by an oxygen-bridge between 
carbon 10 and 7 (δC 85.3 and 77.1 ppm). Compound 4 also has an additional double bond 
between carbon 9 and 11 (δC 135.8 and 122.4 ppm). Both these features are found in literature 
of compound 4 as well (at δC 84.8 and 75.8 ppm for carbon 10 and 7; and δC 135.9 and 121.1 
ppm for carbon 9 and 11). The remaining features, like the sugar moiety and cycloartane type 
triterpenoid structure, is similar to that of compound 5 and 4, thus confirming the skeleton 
structure of compound 4 and its structure to be that of compound 4 (sutherlandioside A); 
which is closely related to compound 5 with the absence of the carbonyl carbon (at position 
1) and the presence of a double bond between carbon number 9 and 11 (see Figure 3.9 for 
structure). The 
13
C and 
1
H spectra of compound 4 can be found in Appendix Figure 5.3 and 
5.4, page 141. HRTOFMS was used to confirm the molecular mass of the compound and its 
characteristic fragmentation patterns. The mass spectrum below (Figure 3.6 below, relating 
to Appendix 4 Figure 4.4, page 134) of compound 4 displays its fragmentation pattern as 
observed in HRTOFMS ESI
-
 and ESI
+
 modes. 
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Figure 3.6 HRTOFMS (ESI
-
 and ESI
+
) for compound 4. 
 
The HRTOFMS ESI
-
 (negative mode) gave a pseudo molecular ion at m/z 651.4080 
(C36H60O10 - H)
-, with a λmax of 203 nm. The mass ion at m/z 697.4157 shows the presence of 
a formic acid adduct (C36H60O10 - H + HCOOH)
-
 due to its presence in the source. An 
elemental composition analysis was done on the m/z 697.4157 and 651.4080 mass ions which 
gave the formulae C37H61O12 and C36H59O10 (which fits the formula M + HCOO
-
 and M - H) 
with an i-FIT value of 0.0 for both fragments, a mass error of -0.6 mDa and -2.8 mDa, 
respectively, and a calculated DBE value of 7 for both fragments (calculated based on the 
molecular formula C36H60O10). The HRTOFMS ESI
+
 (positive mode) shows a pseudo 
molecular peak at m/z 675.3969 (C36H60O10 + Na)
+
. To confirm the presence of the sodium 
adduct at m/z 675.3969 another experiment on the HPLC-MS system was conducted, where 
formic acid was replaced with potassium hydrogen carbonate (KHCO3) in the mobile phase. 
In the mass spectral data below (obtained from the HPLC-SQD), the formation of sodium (in 
positive mode, see Figure 3.8) and formic acid (in negative mode, see Figure 3.7) adducts 
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when the formic acid was used, can be seen, together with the formation of potassium 
adducts when KHCO3 was used (in positive mode, see Figure 3.8) in the ESI negative and 
positive modes. 
 
 
Figure 3.7 ESI mass spectra (ESI
-
) for compound 4 showing the formic acid adduct 
from the SQD system (also found in Appendix 4 Figure 4.5, page 135). 
 
Thus the formation of sodium, formic acid and potassium adducts depended on the ionisation 
mode as well as the mobile phase additives present in the mobile phase.  
In the ESIMS, the pseudo molecular ion at m/z 697.7 (ESI
-
) shows the presence of a formic 
acid adduct (M-H+COOH)
-
. This formation is due to the presence of 0.1 % formic acid in the 
mobile phase (Figure 3.7 top spectrum). This is substantiated by removing the formic acid 
from the mobile phase, thus showing m/z 651.5 (Figure 3.7 bottom spectrum). The formation 
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of the formic acid ion (m/z 697.5) in this case is most likely due to its presence in the source, 
as residual formic acid was not washed out from the source before the following injection. 
The ratio of the molecular ion to the formic acid ion shows the formic acid ion being 
produced from the source. Figure 3.8 below confirms the presence of sodium and potassium 
adducts when the mobile phase is supplemented with formic acid and KHCO3, respectively. 
 
Figure 3.8 ESI mass spectra (ESI
+
) for compound 4 showing sodium and potassium 
adducts from the SQD system (also found in Appendix Figure 4.6, page 135). 
 
In the ESI ESI
+ 
the molecular ion at m/z 675.7 (Figure 3.8 top spectrum) shows the presence 
of a sodium adduct (C36H60O10 + Na)
+
. To confirm this, a potassium buffer (bottom spectrum) 
was used instead of sodium formate, therefore now producing a potassium adduct (m/z 
691.4). This confirms the molecular ion is 652.4206 (C36H60O10), which justifies the claim 
that the isolated compound 4 has the same structure as literature of compound 4, which is 
sutherlandioside A (1S,3R,24S,25-tetrahydroxy-7S,10S-epoxy-9,10-seco-9,19-cyclolanost-
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9(11)-ene 25-O-β-D-glucopyranoside). A typical fragmentation pattern is seen with these 
types of compounds in the MS thus confirming their structures to be related to that of 
compound 5. 
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Figure 3.9 The structure of compound 4 i.e. sutherlandioside A. 
 
Sutherlandioside A was present in very sparse amounts to continue with the biological 
investigations; therefore the activity related to triterpenoids can be seen in fraction IV, where 
four of these related compounds (showing a similar fragmentation pattern in their mass 
spectra) are present in relatively high concentrations. 
3.3.3 Characterisation of compound 7 
Compound 7 was also isolated from extract I from the dried leaves S. frutescens by column 
chromatography on silica gel and sephadex (see Chapter 2 section 2.2.1, page 25). 
Compound 7 displayed a slightly visible spot on a TLC plate under short (254 nm) 
wavelength but not under long (360 nm) wavelength UV light. After the plate was sprayed 
with vanillin reagent and heated at 100 °C for a few minutes, the compound appeared as a 
purple spot with an Rf of 0.2 (solvent system 9:1:0.1 chloroform: methanol: formic acid). 
Only a 0.012 % yield was obtained from the 17.2 g of extract I that was used, whereas a 
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0.019 % yield was obtained from 29.75 g of the same extract from the study done by Fu et 
al., 2008. 
To confirm compound 7‟s chemical profile and obtain its retention time – UPLC-HRTOFMS 
was used. The resulting chromatogram is presented in Appendix 4 (Appendix Figure 4.7, 
page 136). Compound 7 had a retention time of 2.46 minutes in ESI negative and positive 
modes. Further NMR analysis was conducted on the isolated compound 7 to determine its 
structure. The resulting NMR data for compound 7 in methanol-d4 (CD3OD) is presented in 
Table 3.3 below and was compared with data of compounds 5 and 7 found in literature (Fu et 
al., 2008) to determine its structure. 
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Table 3.3 
13
C (600 MHz) data for compound 7 in CD3OD being compared to literature 
data in d-pyr. 
Position Compound 7 Literature *
δC mult. δC mult. 
1 201.9 200.9
2 126 129.6
3 161.1 159.1
4 38.8 37
5 41.8 42.5
6 34.1 31.5
7 70.9 68
8 55.4 52.8
9 34 31.3
10 38.1 35.9
11 27.2 25.8
12 37.1 34.9
13 45.7 45.8
14 51.3 49.8
15 35.6 33.4
16 32.8 29.6
17 53.7 52.5
18 14.8 16.3
19 30.1 29.1
20 40.1 37.5
21 18.3 19.3
22 36.6 34.9
23 28.5 28.5
24 77.2 78.7
25 80.8 81.3
26 21.9 21.6
27 22.3 24.6
28 28.2 28
29 18.8 21.4
30 18.2 19.1
1' 97.3 99
2' 74.6 75.7
3' 77.5 79
4' 71.6 72
5' 77 78.6
6' 64.2 63  
*Literature data from Fu et al., 2008. 
55 
The NMR data of the isolated compound 7 revealed thirty six resonance signals in the 
13
C 
spectrum suggesting that this compound could be compound 5 or closely related. Thus, the 
compound was analysed in deuterated methanol (CD3OD) and compared to what was found 
in literature. Compound 7 showed the absence of one methine group at position 3 (δC 78.1 
ppm found in compound 5), which is substituted with a double bond (δC 126 and 161.1 
ppm). The double bond at position 3 is also found in literature of compound 7 (δC 129.6 and 
159.1 ppm). The remaining NMR assignments for compound 7 are in good agreement with 
literature data of compounds 5 and 7, thus confirming the cycloartane glycosidic structure 
(see Table 3.3 above for 
13
C shifts). Due to the presence of the double bond at position 3, the 
carbonyl group (δC 201.9 ppm), a cyclopropane (δC 34.0, 38.1 and 30.1 ppm), two oxygen-
containing methine groups (δC 70.9 and 77.2 ppm) and a sugar moiety (δC 64.2, 71.6, 74.6, 
77.0, 77.5 and 97.3 ppm); and the absence of a methine group at position 3, in the resulting 
NMR data of compound 7, corroborates the structure to be that of compound 7 (i.e. 
sutherlandioside D). The 
13
C and 
1
H spectra of compound 7 can be found in Appendix 5, 
page 142. HRTOFMS was used to confirm the molecular mass of the compound. The 
spectrum below (Figure 3.10 below, as well as Appendix 4 Figure 4.8, page 137) shows the 
mass spectrum of compound 7 with its fragmentation pattern. 
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Figure 3.10 HRTOFMS (ESI
-
 and ESI
+
) for compound 7. 
 
The HRTOFMS ESI
-
 (negative mode) gave a pseudo molecular ion at m/z 633.4020 
(calculated for C36H58O9 - H)
-
 thereby confirming the accurate mass 634.4093 (C36H58O9) 
found in literature (Fu et al., 2008). There is also the presence of a formic acid adduct ion at 
m/z 679.4002 (M-H+HCOOH)
-
. In HRTOFMS ESI
+
 (positive mode) a distinct fragmentation 
pattern is seen typical of these compounds. Firstly the compound undergoes a loss of about 
m/z 179 which corresponds to the subsequent loss of the hydroxyl groups of the sugar moiety 
resulting in the fragment at m/z 473.3438 and subsequently the loss of the sodium adduct 
(22.9897) which results in the m/z 455.3430. The second (m/z 437.3317) and third (m/z 
419.3214) fragmentations are due to the loss of two water (18.0152 each) molecules (attached 
to carbon 24 and 7). The compound has a λmax of 227 nm. As was done with compound 4, 
the presence of the sodium and potassium adducts was also demonstrated for compound 7. 
The m/z at 657.3832 represents (C36H58O9 + Na)
+
 in the HRTOFMS ESI
+
. The mass spectral 
data that displays the presence of a sodium adduct (m/z 657.7) and a potassium adduct (m/z 
673.4) in HRESI ESI
+
 for compound 7, can be found in Appendix 4 (Appendix Figure 4.9, 
57 
page 137). An elemental composition analysis was done on the m/z 633.4020 which gave the 
formula C36H57O9 (which fits the formula M - H) with an i-FIT value of 0.0 and a mass error 
of 1.9 mDa (value should be < 5) and a calculated DBE value of 8 (which fits the six rings 
and two double bonds of the structure on the molecular formula of C36H58O9). All the above 
data confirmed the structure of the isolated compound 7 to be that of compound 7 (i.e. 
sutherlandioside D - 7S,24S,25-trihydroxycycloart-2-en-1-one 25-O-β-D-glucopyranoside). 
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Figure 3.11 The structure of compound 7 i.e. sutherlandioside D. 
 
The activity of sutherlandioside D in the biological investigations was not determined due to 
its limited amount. In Chapter 6 the activity of fraction IV containing four cycloartane 
glycosides in relatively high concentrations is presented. Sutherlandioside D is also present in 
this fraction in very low concentrations. 
The Table below is a summary of compounds 4, 5 and 7 with their mass spectral data to 
show their correlation with literature data. The UV absorption spectra of all three compounds 
can be found in Appendix Figure 4.10, page 138. Various 2D NMR experiments that were 
run can be found in Appendix 5 pages 143 to 144. 
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Table 3.4 Comparison of mass spectral data of compounds isolated to literature data. 
Samples λmax 
(nm) 
ESI
-
 
(M - H + HCOOH)
-
 
m/z 
ESI
+ 
(M + Na)
+
 
m/z 
Calculated 
mass 
(m/z) 
Literature 
mass 
(m/z)* 
Compound 5 
(Sutherlandioside B) 
219 697.4166 675.4003 652.3997 652.4186 
Compound 4 
(Sutherlandioside A) 
203 697.4114 675.4020 652.3945 652.4186 
Compound 7 
(Sutherlandioside D) 
227 679.4014 657.3832 634.4093 634.4081 
* Literature data from Fu et al., 2008. 
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PART 1 CONT. 
CHAPTER 4 
COMPARISON OF CHEMOTYPES 
 
Six samples of plant material of Sutherlandia frutescens were received from a commercial 
supplier in the Western Cape. These samples were all identified as S. frutescens however, 
upon subsequent growth their morphological appearances differed. In this regard it was 
suspected that there might be different chemotypes of S. frutescens present; resulting in subtle 
chemical differences within the plant species. S. frutescens has been found to be chemically, 
genetically and geographically extremely variable (Van Wyk and Albrecht, 2008). According 
to Moshe et al. (1998), it should be divided into three subspecies and several geographical 
regional forms. The extent to which different chemotypes of S. frutescens exist also makes it 
difficult in selecting the correct plant for research purposes, particularly with regard to 
reproducibility and standardisation of research results. Reliable chemical characterisation 
needs to be in place, in order to avoid incorrect or misleading identification of possible 
species and chemotypes. 
With this background in mind, the purpose of this part of the study was to determine the 
extent of the differences and/or similarities of Sutherlandia frutescens plant material 
collected in one geographical area using HPLC-MS analytical techniques. As previously 
mentioned (page 29), this technique allows for an indication of the compounds present based 
on their molecular masses, which can be subsequently used to identify the structure of the 
compounds. In this chapter, six different samples of Sutherlandia frutescens were 
investigated, by comparing their HPLC-MS chemical profiles, based on similarities and/or 
differences of retention times and mass spectral data. 
 
4.1 UV CHROMATOGRAMS OF CHEMOTYPES 
According to the methodology for generating HPLC-MS-UV data (previously discussed in 
Chapter 2 page 29), the following UV chromatograms for clone samples I to VI are given in 
Figure 4.1 below.  
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Figure 4.1 UV chromatograms of clone samples I to VI. UV-VIS detection was done on 
a WATERS PDA scanning from 200 – 600 nm on the SQD system. 
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Some of the similarities and/or differences are outlined in Table 4.1 below, which point out 
the differences based on retention time and mass spectral data of the major peaks for each of 
the samples. 
Table 4.1 Retention times of the major peaks (and base peak values) found in each 
chromatogram in the UV-VIS range from 200 to 600 nm. 
Sample Retention time (minutes) 
Clone I 10.21 19.84 22.77* 
(255) 
- - 25.93 - - 93.11 
Clone 
II 
10.27 - - 22.72* 
(264) 
- - 26.01 - 93.15 
Clone 
III 
10.19 - - - 25.12 - - 34.53 93.08 
Clone 
IV 
10.21 - - - 25.14 25.92 - - 93.10 
Clone 
V 
10.22 - - - 25.14 - - 34.56 93.09 
Clone 
VI 
10.21 19.79 - 22.60* 
(264) 
- 25.88 - - 92.95 
*Compounds eluting at similar retention times, but have different base peak values (255 
and 264 respectively). 
 
The data in Table 4.1 above shows that there are clear differences between the various 
samples. For example, the peak eluting at 19.84 minutes and 19.79 minutes in clone I and 
clone VI respectively, is absent from the rest of the samples. The similarities in the clone 
samples can also be seen from Table 4.1, such as the peak eluting at 93.11 minutes that 
occurs in high concentrations in all of the samples. Another peak that is present in all the 
samples is the one eluting at 10.21 minutes. This compound appears to be present in all of the 
samples, but in varying quantities, as was reflected by different intensities of the peaks in 
each chromatogram particularly in clones I and V, which had the highest intensities (major 
peaks), whereas in the rest of the samples, lesser peak intensities were observed. It is also 
apparent that there are compounds present that have different base peak values, but with the 
same retention times, thus confirming the presence of compounds with the same polarity, but 
different masses, such as the compounds eluting at 22.77 minutes in clone samples I, II and 
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VI which have a base peak value of 255 and 264, respectively. Based on the data presented in 
Table 4.1 it is clear that there are major differences between the chromatograms. To further 
illustrate differences between the six samples, masses of the eight compounds previously 
isolated from Sutherlandia (compounds 4 to 11 from Fu et al., 2008 and Fu et al., 2010) 
were extracted from the full ESI
-
 data set obtained from the HPLC system and resulting 
chromatograms are displayed below. 
 
4.2 IDENTIFICATION OF SIMILARITIES AND/OR DIFFERENCES OF 
COMPOUNDS 4 TO 11 PRESENT IN THE CHEMOTYPES. 
Figure 4.2 below shows the ES
-
 chromatograms for each of the samples. Differences and/or 
similarities found in the major cycloartane and flavonol glycosides of S. frutescens are 
apparent between samples. The Figure below includes Extract F (MeOH) as a reference 
sample. 
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Figure 4.2 ESI
-
 chromatograms of clone samples I to VI and the reference sample 
obtained from the HPLC SQD system. Extracted masses in ESI
- 
mode: 
739_740+723_724+697_698+679_680+695_696. The peak corresponding to compound 5 
is highlighted in the red block with its structure. 
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From the above chromatograms, variation in the amounts of some of the major compounds 
previously isolated from S. frutescens can be discerned. Differences, based on retention time 
and mass spectral data of these compounds, for each of the samples are shown in Table 4.2 
below. 
Table 4.2 Retention times of the major compounds (and base peak values) found in each 
chromatogram. 
Sample  Retention time (min.) 
Clone I 22.87 - 43.58 - 53.44* 
(695) 
- - 
Clone II 22.85 25.32 43.68 51.15 - 53.45* 
(679) 
59.29 
Clone III 22.43 25.21 - - - - - 
Clone IV 22.81 25.21 43.65 51.11 - 53.46* 
(679) 
59.29 
Clone V 21.75 25.22 43.65 - - - - 
Clone VI 22.82 25.97 43.82 51.21 53.53* 
(695) 
- 59.73 
Reference 
sample 
22.68 25.81 43.66 - 53.18* 
(695) 
- 59.73 
*Compounds eluting at similar retention time, but have different base peak values (679 
and 695 respectively). 
 
The compound eluting at 43.58 minutes in clone sample I was identified to be that of 
compound 5 (based on the standard of compound 5 which was analysed on the same method 
and resulting mass spectral data from the HPLC SQD system). From the chromatograms 
above (in Figure 4.2) clear differences were apparent between some of the flavonoid and 
triterpenoid compounds. The flavonoids were seen to elute from the column between 20.00 
and 30.00 minutes, while the triterpenoids eluted between 40.00 and 65.00 minutes.  
This pattern of elution was also confirmed by mass spectral data. In Figure 4.2 differential 
concentrations of compound 5 occur relative to each sample. Clone samples I and VI were 
seen to contain higher concentrations of compound 5 (with 2298223.16 and 2638843.18 
counts respectively) which was completely missing from clone III and very small amounts in 
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clone V (with only 60590 counts) All the clone samples contain the flavonoid compound 
eluting at 22.87 minutes, which has a m/z of 763, corresponding to either compounds 8 or 9.  
More variation was seen to occur with the other two flavonoids (compounds 10 and 11). 
Clone samples I and VI and the reference sample have similar profiles for these compounds, 
with clone VI demonstrating more complexity. Compounds eluting at 53.36 minutes in 
clones I, II, IV and VI all have the same retention times, but different base peak values 
implying that they are different compounds. Clones I and VI and the reference sample 
contain the same compound (with a base peak
 
of 695), while clones II and IV have a 
compound with a base peak value of 679.  
Based on the data presented in the Table 4.1 and 4.2, it is clear that there are major 
differences between the detected peaks observed in these chromatograms. On the basis of 
having comparable quantities of compound 5, but differing amounts of the other compounds, 
three groups can be identified, namely clones I and VI, clones III and V, and clones II and 
IV. The compounds found in the reference sample were found to be more complex than the 
clone samples, but was similar to clone sample VI. This was also confirmed in the literature, 
where Chinkwo (2005) noted differences in the anti-cancer activity of the aqueous extracts of 
the plant material that was collected from different locations, all being identified as S. 
frutescens. This corroborates our findings on the variations found in the plant material. The 
full chemical profiles of each of the samples can be found in Appendix 6 Figure 6.1, page 
145. 
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PART 1 CONT. 
CHAPTER 5 
PHYTOCHEMISTRY CONCLUSION  
 
From the analyses done on the extracts, it was concluded that the aqueous extract of the fresh 
leaves (extract A) contained more compounds than the aqueous extract of the dried leaves 
(extract D). The freeze drying process was found to be more suitable for controlling stability 
of some compounds, compared to the spray drying process, which degraded some of the 
compounds present (extract D vs. extract K). The organic preparations were found to 
contain more of a variety of compounds, especially from 40.00 through to 90.00 minutes (the 
triterpenoid and non-polar regions). The HPLC SQD and UPLC TOFMS analysis of the 
compounds displayed a characteristic pattern that was challenging to elucidate. The 
characteristic cycloartane glycosides formed a sodium adduct on the pseudo molecular ion in 
positive mode, plus a formic acid adduct in ESI
-
 mode, if formic acid was present in the 
mobile phase or source. The structures of compounds 4 and 7 that were isolated (in low 
yields) from the butanol extract (Extract I) were confirmed to be sutherlandioside A and D 
using NMR and UPLC-TOF-MS data analyses [1S,3R,24S,25-tetrahydroxy-7S,10S-epoxy-
9,10-seco-9,19-cyclolanost-9(11)-ene 25-O-β-D-glucopyranoside (4) and 7S,24S,25-
trihydroxycycloart-2-en-1-one 25-O-β-D-glucopyranoside (7)]. Although Fu and co-workers 
(2008) obtained higher yields of the cycloartane glycosides, it could be possible that the 
batches of plant material might be that of different subspecies, thus containing varying 
amounts of the compounds. Further investigations on different purification techniques for the 
various subspecies should be done, in order to investigate a better way of purifying these 
compounds to give higher yields and also to provide standards for the market. Mass directed 
fractionation (for the cycloartane glycosides) and/or counter-current chromatography (for the 
flavonol glycosides) might have provided for easier purification methods. The flavonol 
glycosides need to be handled with care due to their observed tendency to degrade. Higher 
volumes of extract material should ideally be subject to optimised purification techniques in 
order to obtain better yields of the resulting compounds.  
From the comparison of the six chemical profiles of the S. frutescens samples (presented in 
Tables 4.1 and 4.2) it was clear that major differences between the various peaks in the 
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chromatograms were present. As such, this showed clear differences in the plant material 
collected from a single geographical location, supporting the morphological differences seen. 
These results point to the fact that there are significant chemical differences within this plant 
species, as was reflected in the plant material of the different cultivars, obtained from the 
same commercial supplier, which have manifested as different chemotypes. Based on the 
presence and amounts of compound 5, three similar groups were identified namely, clone 
samples I and VI, clone samples III and V, and clone samples II and IV.  
On the basis of these initial findings, it is recommended that care should be taken when 
selecting S. frutescens plant samples for research and commercialization purposes, etc. For 
example, correct identification of subspecies needs to be done and commercial products need 
to be standardised on a single subspecies. Mixing of samples should be avoided. 
Documentation to trace back the source of the plant material should be well recorded. All 
future research should identify the plant material according to subspecies and database the 
related activities to avoid ambiguous information. Further investigations on the activities of 
the different chemotypes, together with a qualitative analysis of the compounds present, 
should be carried out in future, so as to obtain the most suitable chemotype to be used for 
subsequent cultivation, research and standardisation purposes. 
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PART 2 
BIOLOGICAL INVESTIGATIONS 
CHAPTER 6 
MATERIALS AND METHODS 
 
The use of medicinal plants and the investigation of their pharmacological activities is a very 
important aspect in drug discovery. Very often various scientific studies have found that a 
plant extract or isolated chemical compound from the plant has pharmacological activity 
which supports traditional uses. However, in order to provide scientific credibility on the 
plant extracts or isolated compounds‟ role in our immune system or on foreign 
microorganisms, along with their optimal dose and duration, further investigations on their 
pharmacological impacts need to be undertaken.  
One of the ways to discover possible mechanisms associated with medicinal plants is via 
various pharmacological assay systems. Once protocols for various preparations of these 
plants have been established, an important aspect for the discovery of new drugs, for various 
diseases, would be to analyse these preparations for different kinds of biological activity. In 
this study, various biological activities were performed on the extracts of the aerial parts of S. 
frutescens prepared in Part 1. In particular, anti-cancer and cytokine release assays were 
performed using in vitro assay systems on the resulting extracts, fractions and compounds. 
This chapter presents a detailed discussion of the materials and methods used to biologically 
investigate the extracts prepared and compounds isolated from S. frutescens. 
 
6.1 TISSUE CULTURE TECHNIQUES 
Tissue culture is a general term used to cover methodologies for the removal of cells, tissues, 
or organs from an animal or plant and their successive placement into an artificial 
environment favourable for growth (Ryan, 2008). These methodologies form an important 
part of molecular biology and are crucial to building our understanding of a range of disease 
mechanisms and their subsequent treatment. According to Ryan (2008), these methodologies 
are also as important in forming an in vitro model system for rational drug discovery and 
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development. In this study, HL60 (human promyelocytic leukaemia) cells were used to study 
the effects of extracts made from S. frutescens on the cancer cell line and subsequent release 
of cytokines were measured. To extend the range of potential effects of selected extracts on 
other cancer cells, two additional cell lines, namely MCF7 and UACC62 were also used. 
Primary macrophage cells isolated from whole blood were used to determine toxicity. 
6.1.1 Materials 
RPMI-1640, Fetal Bovine Serum (FBS) and L-Glutamine were purchased from Whitehead 
Scientific. Gentamicin, Phorbol 12-Myristate 13-Acetate (PMA) and Etoposide standards 
were purchased from Sigma Aldrich. The anti-cancer screening assay involved 
Sulforhodamine B staining of treated cells developed by Skehan et al. (1990). The 
Cytometric Bead Array™ Human Inflammation Cytometric Bead array (CBA) kit (551811) 
was purchased from BD Biosciences and analysed using BD Biosciences‟ equipment and 
software. The protocol for the isolation of macrophages from whole blood was followed 
according to Rice and Hermann Laboratory protocols, which was performed by Dr. S. 
Barichievy
4
.  
6.1.2 Tissue culturing 
6.1.2.1 Pre-preparations of laboratory  
Aseptic techniques were adhered to, as well as personal protective equipment was worn at all 
times during culturing of cells in the tissue culture laboratory. To minimise contamination of 
cell cultures, all work surface areas and materials were sterilised with 70 % ethanol before 
and after any procedure. Where appropriate, all materials used were sterilised by autoclaving. 
Cell culture work was performed in a Biosafety II cabinet equipped with a vertical laminar 
flow hood and UV light. 
6.1.2.2 Maintenance of cells 
Commercially available cell lines, being HL60, MCF7 and UACC62 cells, originally isolated 
from leukaemia, breast adenocarcinoma and melanoma cancer patients, respectively, were 
used. The cancer cell lines UACC62 and MCF7 were obtained from the National Cancer 
Institute (NCI) in a framework of collaborative research program between the Council for 
                                                          
4
 Dr. Samantha Barichievy, Emerging Health Technologies, Biosciences, CSIR, Pretoria 
SBarichievy@csir.co.za  
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Scientific and Industrial Research (CSIR) Biosciences and NCI. The HL60 cell line was 
obtained from the European Collection of Cell Culture (ECACC). The macrophage cells 
obtained from the Gulf Coast Blood Regional Blood Centre are pathogen-negative 
leukopacks (which contain 50 ml leukocytes enriched from 450 ml whole blood).  
The derived cell lines used in this study, as well as other isolated cells, required specialised 
environments for their successful culture and growth. The essential requirements for an 
optimum cell culture environment include temperature, pH, gas phases and media which 
contained necessary nutrients. For this study, RPMI-1640, supplemented with foetal bovine 
serum (FBS), L-glutamine and gentamicin was used for culturing of the cell lines. Glutamine 
is essential for cells that have a high energy demand and synthesise large amounts of proteins 
and nucleic acids. It is an alternative energy source for rapidly dividing cells that use glucose 
inefficiently. Although L-glutamine is synthesised by all normal cells, transformed cancerous 
cells are dependent on exogenous sources (ECACC handbook, 2006). Gentamicin was 
included to control bacterial contamination of the cultures. 
Cell lines were routinely maintained, either as a monolayer cell culture (UACC62 and MCF7) 
or in suspension (HL60), at 37 °C in 5 % carbon dioxide (CO2) and 100 % relative humidity 
in RPMI-1640 supplemented with 5 % FBS, 2 mM L-glutamine and 50 µg/ml gentamicin. 
Splitting of cells was done at least twice weekly. UACC62 cells are long elongated cells and 
can form round cells at confluence. They have a doubling time of 31.3hrs, while MCF 7 cells 
are small round cells and fast growing with a doubling time of 25.4hrs. HL60 cells have a 
doubling time of 28.6 hours. Sub-culturing was performed on the cell lines while growing in 
the exponential growth phase, which was dependent on the confluence of cells and their 
growth rate in each flask. 
The process of sub-culturing for HL60 cells (in suspension) involved centrifugation (at 
1 000g for 2 min.), to remove the media and subsequently splitting the cells into two new 
flasks with newly prepared RPMI-1640 media. A small quantity (100 µl) of the cell 
suspension was used for cell quantification and determining seeding density (see section 
6.1.2.3 below). The process of sub-culturing for UACC62 and MCF7 cells (adherent cells) 
involved decanting of spent media, adding trypsin to detach cells from the surface and 
subsequently collecting the cells by centrifugation. The collected cells were then split into 
two new flasks with fresh culture media. 
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The preparation of primary human macrophages from the leukopacks was followed according 
to the standard Rice and Hermann Laboratory protocols and was performed by Dr. S. 
Barichievy. Thereafter, the viable macrophage cells were subjected to the standard protocols 
followed with the cancer cell lines. This included cell quantification and seeding density as 
well as the standard NCI protocol for cancer cell viability (see sections 6.1.2.3 and 6.2 below, 
pages 71 and 72). 
6.1.2.3 Cell quantification and seeding density 
This was done with a haemocytometer and viewed under a light microscope (20x 
magnification). A 100 µl cell suspension was mixed with an equal volume of trypan blue and 
applied to the haemocytometer slide, where viable cells appear bright and dead cells are 
stained blue. To determine seeding density the following calculation was used: 
Total number of viable cells/ml = Average count per square x dilution factor x 10
4 
Dilution factor = 2 (volume of cell suspension and trypan blue 1:1) 
10
4
 = correction factor (supplied by manufacturer) 
For seeding 10 000 cells/well in a volume of 100 µl = total number of viable cells/ml / 
100 000 
6.1.2.4 Cryopreservation of cells 
For cryopreservation of cells, a flask was identified and viewed under the microscope to 
assess the degree of cell density and cell viability. Trypsinised cells were then sedimented at 
1 000g for 2 min. to remove the culture medium which was then replaced with 6 ml of 
cryopreservation medium (10% DMSO in RPMI). One ml each of this suspension was 
aliquotted into sterile vials (approx. 1 000 000 cells / vial) and placed in the freezer at -20 °C 
for 2 to 3 hours, then subsequently removed and placed in the -70 °C freezer and finally in a 
liquid nitrogen container, to ensure a slow temperature decline to prevent cell damage. When 
cells were needed, they were quickly thawed from a cryovial and immediately placed in 
warm media and incubated overnight. The old media was removed after this incubation 
period and cells were placed in fresh RPMI-1640 media. 
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6.2 ANTI-CANCER AND MACROPHAGE CELL SCREENING  
Standard NCI Protocol for Cancer Cell Viability Assay 
The SRB assay was performed in collaboration with the Pharmacology group at the CSIR in 
accordance with the protocol of the Drug Evaluation Branch, National Cancer Institute (NCI) 
(Monks et al., 1991; Kuo et al., 1993; Leteurtre et al., 1994). Following the protocol 
developed by Skehan et al. (1990) as a standard NCI protocol for anti-cancer drug screening. 
Its principle is based on the ability of the protein dye sulforhodamine B to bind 
electrostatically in a pH-dependent manner to protein basic amino acid residues of 
trichloroacetic acid-fixed cells. Under mild acidic conditions, the dye binds to the fixed 
cellular proteins, while under mild basic conditions; it can be extracted and solubilized for 
spectrophotometric measurement at 540 nm. 
For screening purposes the cells (3 to 19 passages) were inoculated in a 96-well microtiter 
plate at plating densities of 7 to 10 000 cells/well and incubated for 24 hours. After 24 h, one 
plate was fixed with 50 % trichloroacetic acid (TCA) to represent the measurement of the cell 
population for each cell line at the time of drug addition (T0). The other plates with cells were 
treated with experimental drugs which were previously dissolved in dimethylsulfoxide 
(DMSO) and diluted in media to the desired final test concentrations (100, 50 and 25 µg/ml). 
The final concentration of DMSO in the cell culture media of all of the wells i.e., control plus 
experiment did not exceed 1 % (v/v). This approach, with residual DMSO being present in 
the cell culture media, was in line with the protocol developed by Skehan et al. (1990). 
Cells without drug addition served as a control. The blank contained complete cell culture 
media without cells. Etoposide was used as a positive control for the anti-cancer assay. The 
effect of PMA on the cancer cells was determined for a 6 and 48 hour incubation period at 
12.5 and 6.25 ng/ml. The plant extracts were screened at 100, 50 and 25 µg/ml for a 48 hour 
incubation period. See Table 6.1 below for plate setup for cancer cells and samples. 
The plates were then incubated for 48 hours; viable cells were fixed to the bottom of each 
well with cold 50 % TCA (for UACC62, MCF7 and macrophages) and 80 % TCA (for 
HL60), for approximately 1 hour. The TCA was washed off with tap water and left to dry 
completely in the fume hood for 15 min. After this, the SRB dye (100 µl) was added to each 
well and left for 10 min. Unbound SRB dye was washed off with 1 % acetic acid and protein-
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bound SRB dye was extracted with 10 mM Tris. The optical density was determined at a 
wavelength of 540 nm, using a multiwell spectrophotometer. 
Cell viability (V) was calculated with the following formula and expressed as a 
percentage: 
% V = (T - blank) / (Ctrl - blank) * 100 
Where T = Optical density of the test well after 48 hours of exposure to the test drug, 
and 
Ctrl = Optical density of the control (untreated cells after 48 h incubation) 
The control (Ctrl) is set at 100 % viability of cells. For cells > 100 %, the drug favours cell 
growth and for cells < 100 %, the drug causes a reduction of proliferation of cells (cell death). 
IC50 is found when a drug reduces the growth of the cells by 50 % less than the amount of the 
control. As this assay was based on a standard viability cell assay used by the NCI according 
to Skehan et al. (1990), no additional controls were included to determine the effect of any 
residual organic solvents that might have been present in the plant extracts. From a cell 
culture quality control perspective, the direct effect of DMSO [at 1 % (v/v) or less] on the 
cancer cells has previously been shown to have a negligible effect, as validated by NCI and 
the CSIR Pharmacology group. DMSO at higher concentrations has been shown to affect cell 
viability (Cheah et al., 2009). 
Table 6.1 96-Well microtiter plate setup for cancer screen. 
 1 2 3 4 5 6 7 8 9 10 11 12  
A Control Control Drug1 Drug2 Drug3 Drug4 Drug5 Drug6 Drug7 Drug8 Drug9 Drug10 <-No cells 
B Control Control Drug1 Drug2 Drug3 Drug4 Drug5 Drug6 Drug7 Drug8 Drug9 Drug10 <-UACC62 
C Control Control Drug1 Drug2 Drug3 Drug4 Drug5 Drug6 Drug7 Drug8 Drug9 Drug10 <-UACC62 
D Control Control Drug1 Drug2 Drug3 Drug4 Drug5 Drug6 Drug7 Drug8 Drug9 Drug10 <-MCF7 
E Control Control Drug1 Drug2 Drug3 Drug4 Drug5 Drug6 Drug7 Drug8 Drug9 Drug10 <-MCF7 
F Control Control Drug1 Drug2 Drug3 Drug4 Drug5 Drug6 Drug7 Drug8 Drug9 Drug10 <-HL60 
G Control Control Drug1 Drug2 Drug3 Drug4 Drug5 Drug6 Drug7 Drug8 Drug9 Drug10 <-HL60 
H Control Control Drug1 Drug2 Drug3 Drug4 Drug5 Drug6 Drug7 Drug8 Drug9 Drug10 <-No cells 
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6.3 QUANTIFICATION OF CYTOKINE RELEASE 
Cytokines are small molecular weight messenger proteins that are produced by cells of the 
immune system in response to a stimulus (Lydyard, Whelan and Fanger, 2004; O‟Gorman 
and Donnenberg, 2008). They mediate chemical communication between the cells as well as 
a variety of other induced functions, including modulation of many biological pathways 
controlling growth, differentiation, activation of cells and/or programmed cell death. 
Cytokine production in HL60 cells only was analysed in supernatants of cells cultured for 48 
h with test samples using Cytometric Bead Arrays™ (BD Biosciences). The samples were 
analysed on the BD FACSCalibur™ platform which offered a unique modular approach to 
flow cytometry. The BD FACSCalibur flow cytometer was designed with multicolour 
applications to provide flexibility for a wide variety of research and clinical applications 
(www.bdbiosciences.com). The HL60 cells were counted and seeded (100 µl/well) at the 
recommended density (10 000 cells/well) in a 96-well microtiter plate and incubated for 24 h. 
Media was added to some wells as a control. The test samples were prepared in media for a 
final concentration of 25 µg/ml (in the wells) and added to the wells (50 µl). The plate was 
then incubated for 42 h. PMA at 12.5 ng/ml was used as a stimulant for some samples and 
only added to the 42 h plate for a 6 hour incubation period. Each well contained a final 
volume of 200 µl. See Table 6.2 below for plate setup. After a total of 48 hrs incubation 
time, the plate was removed and centrifuged for 2 min. at 1 000g, supernatants (50 µl) from 
each well were removed and placed in Eppendorf tubes separately and frozen (at -80 °C) until 
use. 
The IL12p70, TNF, IL10, IL6, IL1β and IL8 cytokines were detected using the human 
inflammation CBA kit (551811; BD Biosciences). Tests were performed according to the 
manufacturer‟s instructions. Briefly, 50 µl of the supernatants was mixed with 50 µl of all 6 
cytokine capture beads (IL12p70, TNF, IL10, IL6, IL1β and IL8) and 50 µl of PE detection 
reagent (phycoerythrin-conjugated anti-human cytokine antibodies). The six bead populations 
are mixed together to form the BD CBA, which is resolved in a red channel (i.e. FL3 or FL4) 
of a BD flow cytometer. For each set of experiments, a standard curve was generated. After a 
3 hour incubation period, samples were rinsed, resuspended in phosphate buffered saline 
(PBS) and analysed by flow cytometry (FACScan with the CBA Analysis Software; BD 
Biosciences). Flow cytometry was performed with a BD technician at University of Pretoria 
on a BD FACSCalibur flow cytometer. The results were expressed as pg/ml and then 
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analysed for their relative expression (control versus treated samples). The lower limit of 
detection for each cytokine was determined as 10 pg/ml. 
Table 6.2 96-Well microtiter plate setup for CBA. 
 1 2 3 4 5 6 7 8 9 10 11 12  
A Control Drug1 Drug2 Drug3 Drug4 Drug5 Drug6 Drug7 Drug8 Drug9 Drug10 Drug11 <-HL 60 
B Control Drug1 Drug2 Drug3 Drug4 Drug5 Drug6 Drug7 Drug8 Drug9 Drug10 Drug11 <-HL 60 
C Control Drug1 Drug2 Drug3 Drug4 Drug5 Drug6 Drug7 Drug8 Drug9 Drug10 Drug11 <-HL 60 
D Control Drug1 Drug2 Drug3 Drug4 Drug5 Drug6 Drug7 Drug8 Drug9 Drug10 Drug11 <-HL 60 
E PMA Drug1 
+PMA 
Drug2 
+PMA 
Drug3 
+PMA 
Drug4 
+PMA 
Drug5 
+PMA 
Drug6 
+PMA 
Drug7 
+PMA 
Drug8 
+PMA 
Drug9 
+PMA 
Drug10 
+ PMA 
Drug11 
+ PMA 
<-HL 60 
F PMA Drug1 
+PMA 
Drug2 
+PMA 
Drug3 
+PMA 
Drug4 
+PMA 
Drug5 
+PMA 
Drug6 
+PMA 
Drug7 
+PMA 
Drug8 
+PMA 
Drug9 
+PMA 
Drug10 
+ PMA 
Drug11 
+ PMA 
<-HL 60 
G PMA Drug1 
+PMA 
Drug2 
+PMA 
Drug3 
+PMA 
Drug4 
+PMA 
Drug5 
+PMA 
Drug6 
+PMA 
Drug7 
+PMA 
Drug8 
+PMA 
Drug9 
+PMA 
Drug10 
+ PMA 
Drug11 
+ PMA 
<-HL 60 
H PMA Drug1 
+PMA 
Drug2 
+PMA 
Drug3 
+PMA 
Drug4 
+PMA 
Drug5 
+PMA 
Drug6 
+PMA 
Drug7 
+PMA 
Drug8 
+PMA 
Drug9 
+PMA 
Drug10 
+ PMA 
Drug11 
+ PMA 
<-HL 60 
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PART 2 CONT. 
CHAPTER 7 
RESULTS AND DISCUSSION  
FOR  
ANTI-CANCER AND CYTOKINE ASSAYS 
 
The use of medicinal plants and the investigation of their pharmacological activities is a very 
important aspect in drug discovery. In order to provide preliminary scientific credibility on 
the role S. frutescens plays with its natural aspects, specific focus on the extracts, fractions 
and compounds of S. frutescens; with their influence on cancer cells and release in cytokines 
with phorbol 12-myristate 13-acetate (PMA) as a co-stimulant, as well as a brief look into the 
effect of one extract on macrophage cells was investigated. A variety of factors govern the 
study of medicinal values of plant extracts, including solutes used in the extraction procedure, 
the concentration of the extracts being applied, together with the exposure time (Ngcobo, 
2008). As a result, a number of organic and aqueous extracts, prepared from S. frutescens in 
Part 1, with varying concentrations on cultured cells were investigated for biological 
activities and discussed in this chapter. 
 
7.1 CANCER CELL SCREENING  
In order to investigate the viability (V) effects of the extracts on the cancer cells in a 3-cell 
line panel consisting of UACC62 (melanoma), MCF7 (breast) and HL60 (leukemia) cells; the 
SRB assay was performed, in collaboration with the Pharmacology group at the CSIR in 
accordance with the protocol of the Drug Evaluation Branch, NCI (Monks et al., 1991; Kuo 
et al., 1993; Leteurtre et al., 1994). The SRB assay was developed by Skehan et al. (1990) to 
measure drug-induced cytotoxicity and cell proliferation. The discussion that follows below 
will look at selected extracts, fractions and compound‟s response on cell viability for each of 
the UACC62, MCF7 and HL60 cell lines. 
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7.1.1 Control 
The graphs below (i.e., Figure 7.1) express the three cancer cell‟s viability (in percentage) 
relative to their control. The control (Ctrl) contains untreated cancer cells that undergo 
normal incubation conditions and its values are set as 100 % to represent their natural growth.  
Ctrl 12.5 (48h) 6.25 (48h) 12.5 (6h) 6.25 (6h)
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Figure 7.1 Viability of UACC62, MCF7 and HL60 treated with PMA dilutions at 12.5 
and 6.25 ng/ml over a 48 and 6 hour incubation period. 
 
7.1.2 Phorbol 12-Myristate 13-Acetate (PMA) 
Varying the PMA exposure time on the cancer cells (i.e., for 48 and 6 hour incubation period) 
and concentration (i.e., for 12.5 and 6.25 ng/ml), its effect on the cancer cells viability has 
been studied and presented in Figure 7.1 above. In this study, a marginal decrease in cell 
viability, when cultured in the presence of PMA, was observed. Irrespective of the 
concentration of PMA used on the target cells, no differential effect was observed in the 
assay system. Over the course of a 6 hour incubation period, the MCF7 cells were observed 
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to increase in viability, but when the culture system was exposed for a longer duration (48 
hours), there was about a 10 % decrease in cell viability, irrespective of the PMA 
concentration. This could possibly be a hermetic effect exhibited by the MCF7 cells.  
Both the UACC62 and HL60 cell lines decreased in cell viability for the 6 and 48 hour 
incubation periods at both concentrations of PMA. It was interesting to note that the effect of 
PMA on UACC62 cells increased the viability over a longer duration (i.e., at 48 hrs where V 
decreased only by about 20 %) as compared to the 6 hour incubation period (where V 
decreased by about 37 %) at both concentrations of PMA (6.25 and 12.5 ng/ml). This 
indicated that the UACC62 cells were able to develop some mechanisms that resisted the 
effect of PMA through time or that some of these cells contained a PMA resistance 
mechanism that allowed their survival with subsequent increase in total number per culture 
well over time. In the case of the HL60 cells, there was a reduction in cell numbers over time, 
with respectively 20 and 50 % decrease in cell viability for the 6 and 48 hour incubation 
periods (with an IC50 on the HL60 cells, for the 48 hrs).  
From these observations, PMA showed a time-dependant outcome on cell viability, rather 
than a dose-dependent consequence (V variation for time varied from 13 to 40 % and V 
variation for dose varied from 0.3 to 7 %). One of the limitations of this experiment was that 
it did not reflect the kinetics of cell growth (and death) over the full 48 h incubation period. 
As such, the kinetics of cell death were not followed throughout, therefore no conclusions can 
be made as to whether the increased cell growth at 48 h was due to a resistant clone of cells 
or whether a resistance mechanism was induced over this period to counteract possible 
toxic/negative agents in the medium.  
PMA, which was used as a mitogen, has been known to inhibit MCF7 cell growth, but 
simultaneously stimulate cell survival (Fortino et al., 2008). A study done by Wright and 
Meyer (1986) showed the binding affinity of soluble immune complexes (on phagocytosis-
promoting receptors) was intensively decreased upon stimulation of polymorphonuclear 
leukocytes (PMN) with PMA. Wright and Meyer attributed this result to a dephosphorylation 
event initiated by PMA. Another study done by Bigby et al. (1990), illustrated the down-
modulation of CD4 expression induced by PMA in various cell types, including the human 
lymphoblastic leukaemia cell line (MOLT-3), which resulted in a down regulation of an 
immune response and coincided with a decrease in cell viability. In addition, they indicated 
that PMA activated protein kinase C could cause a cascade of down regulation in the 
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expression of CD4 and CD8 cells, which are required for further initiation of an immune 
response and ultimately resulted in a decrease in cell viability. Responses obtained from the 
addition of the plant extracts on the cancer cells will be discussed in the following sections.  
7.1.3 Effect of plant extracts on cancer cell growth 
The experimental cancer cells that were exposed to selected preparations of S. frutescens 
showed either a decrease or increase in cell viability relative to the control. An increase in V 
above 100 % showed that the extracts stimulated cancer cell growth to a greater extent than 
that of the normal incubation conditions.  
7.1.3.1 Organic extracts  
Ethanol and butanol extracts were tested for their anti-cancer response at 100, 50 and 25 
µg/ml over a 48 hour incubation period, as discussed in Chapter 6 section 6.2 (page 72). 
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Figure 7.2 The effect of extracts C and I on cancer cell viability at 100, 50 and 25 µg/ml 
over a 48 hour incubation period. 
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In Figure 7.2 an inversely proportional relationship was observed between increasing 
concentration of extracts and cell viability for both ethanol (Ext C) and butanol (Ext I) 
extracts. A variable sensitivity was observed for each cell line, with the HL60 cells being 
more susceptible to variations in concentration of the two extracts than that of MCF7 and 
UACC62 cells (with UACC62 being relatively the least sensitive).  
Cells cultured in the presence of the ethanol extracts, irrespective of the concentration, 
displayed a decrease in viability, with the exception of MCF7 at 25 µg/ml (approx. V ≈ Ctrl), 
demonstrating the effective anti-cancer properties of this preparation. Stander et al., (2007) 
reported that an ethanolic preparation of the leaves of S. frutescens inhibited cell growth of 
MCF7 cells with an IC50 of 1.5 mg/ml over 24 hours, as well as throughout a 72 hour time-
dependant study, with intervals of 24, 36, 48 and 72 h. Their morphological analysis 
demonstrated an increase in apoptotic cells, suggesting that Sutherlandia might induce its 
growth inhibitory effects through an initiation of apoptosis on the MCF7 cells. 
Furthermore, the interpolation of experimental data points of the ethanol extract showed that 
for MCF7 and HL60 cell lines, the IC50 corresponded to 93 and 74 µg/ml, being respectively, 
lower than those found by Stander et al. (2007). However, for UACC62 cells the IC50 values 
were different for the ethanol (97 µg/ml) and butanol (75 µg/ml) extracts (the interpolation 
graph is not shown). Both extracts showed a large decrease in V (more than the IC50) at 100 
µg/ml, with the butanol extract being more toxic. This finding might be due to the presence 
of an increased concentration of cycloartane-type triterpenoid compounds, compared to the 
ethanol extract. These compounds are believed to have potent anti-cancer properties, as was 
shown in the study done by Kikuchi et al. 2007. 
For all three concentrations of the butanol extract, there was an additional increase in MCF7 
cell viability at 50 and 25 µg/ml, relative to the Ctrl. The increase in viability of MCF7 cells 
cultured in the presence of less saturated butanol extracts provided some evidence that the 
breast cancer cells were able to develop some regulating mechanisms that were able to 
promote their growth in the presence of the extracts over and above that of the normal 
environmental conditions. Kundu and co-workers (2005) have shown that a methanolic 
extract of Sutherlandia (at 100 and 200 µg/ml) inhibited 12-O-tetradecanoylphorbol-13-
acetate (TPA)-induced cyclooxygenase-2 (COX-2) expression in mouse skin cells, thereby 
providing additional evidence that the extracts of S. frutescens exhibit anti-tumour potential. 
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Aqueous extracts, in this study, displayed a less toxic effect on cancer cell V at lower 
concentrations than the organic preparations, as can be seen in Figure 7.3 below. 
7.1.3.2 Aqueous extracts  
A traditional extraction procedure was followed, resulting in extracts A, B, D and K which 
were prepared using different plant parts (leaves and stems) and comparing fresh to dry plant 
material (Part 1 pages 19 to 24). Customarily, a tea infusion of the dried leaves is used by the 
traditional healers. For comparative purposes, different extracts were prepared to help 
determine the most effective preparation with the most efficient biological activity for further 
use and further investigations. The influence of these extracts (at 100, 50 and 25 µg/ml) on 
different cancer cell‟s viabilities is shown below in Figure 7.3.  
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Figure 7.3 The effect of extracts A, B, D and K on cancer cell viability at 100, 50 and 25 
µg/ml over a 48 hour incubation period. 
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For the aqueous extracts an inversely proportional relation was also observed between 
increasing concentration of extracts and cell viability. The aqueous extracts (A, B, D and K), 
at 25 µg/ml, all favoured the growth of the HL60 cells more than that of the other cancer cells 
(V = 113, 110, 109 and 120 %, respectively for HL60 cells). However, the aqueous extracts 
of the fresh plant material (extracts A and B) were found to be more toxic to the cancer cells 
at 100 µg/ml (showing on average a decrease in V for all three cell lines of about 75 and 69 
% for A and B respectively) than the aqueous extracts of the dry plant material (D), which 
exhibited an average decrease in V by about 40 %. Aqueous extracts prepared from the fresh 
plant material were shown to have significant growth retarding effects on the cancer cell lines 
at concentrations of 100 µg/ml, irrespective of the part of the plant used (leaves or stems). At 
lower concentrations of the aqueous extracts (e.g. at 25 µg/ml) stimulation of cell growth was 
observed. Compared to the other two cell lines used in this study, the HL60 cells were found 
to be more sensitive to a change in concentration of the extracts. This might have been due to 
the nature of the cells, together with the greater solubility of the more polar compounds 
extracted when these extracts were prepared. In support of this contention, chemical profiles 
of the extracts shown in Appendix 2 (page 122), displayed a higher concentration of polar 
compounds being extracted compared to their non-polar counterparts.  
In contrast, there was a loss in anti-cancer activity in the aqueous extract of the dry plant 
material (extract D), compared to the aqueous extracts of the fresh plant material. This loss 
in activity could be due to the unstable nature of some of the active compounds extracted 
with water, as well as the natural drying process used in preparing these extracts, which 
might have changed the active chemical structures, resulting in a higher concentration of 
dormant compounds. The spray dried aqueous extract (K) in Figure 7.3 was shown to be less 
toxic (with an average cell viability of around 42.6% for all three cell lines) compared to the 
aqueous extracts of the fresh plant material (which were freeze dried), but with slightly more 
potent effects than the freeze dried extract (D) at 100 µg/ml. A time and dose dependant 
study by Chinkwo (2005) showed differences in the anti-cancer potential of the aqueous 
extracts of S. frutescens on cervical carcinoma cell lines, but also noted differences in activity 
of plant material collected from different locations.  
7.1.3.3 Echinacea tincture (Ech) 
Echinacea (see Figure 7.4 below), which was used as a positive control for immune-
modulating abilities on cultured cells, was also examined for its anti-cancer properties, to 
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compare with the Sutherlandia preparations. Etoposide, which was used as an anti-cancer 
standard, displayed an IC50 at 46 µg/ml for the HL60 cells. 
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Figure 7.4 The effect of etoposide and Echinacea on cancer cell viability at 100, 50 and 
25 µg/ml over a 48 hour incubation period. 
 
As seen with the other traditional and organic plant preparations, Echinacea also exhibited a 
negative impact on cancer cell V as the concentration increased, which was also cell 
dependant. Nevertheless, its negative impact on cancer cell viability was lower than the 
Sutherlandia preparations. The impact of Ech on the HL60 cells was less than the other 
cancer cell lines (average V = 87 % at all three concentrations for HL60 cells). Also, the 
interpolation of experimental data points showed that for UACC62 and MCF7 cells the  IC50 
values corresponded to about 100 µg/ml for both cell lines (the interpolation graph is not 
shown) higher than that of the Sutherlandia extracts. 
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The active compounds in Echinacea are known as alkylamides and are responsible for its 
immuno-modulatory properties (Raduner et al., 2006). The activity of Echinacea could 
possibly be attributed to the interaction of the active alkylamide compounds with the cancer 
cells. From these results, it can be concluded that the S. frutescens preparations exhibited 
more potent anti-cancer potential compared to when the cancer cells were cultured with 
Echinacea. This finding could probably be due to the complex nature of the compounds 
present in S. frutescens, thereby providing further validation for the traditional uses of S. 
frutescens as an herbal remedy.  
7.1.3.4 Fractions  
The ethanol extract was further fractionated into three fractions using a C-18 cartridge 
namely, fractions I, II and III, representing a polar fraction, a fraction containing 
triterpenoid-type compounds (which are less polar in nature than the polar fraction) and a 
fraction containing the non-polar compounds that are found in the ethanol extract (see Part 1 
page 25 as well as Appendix 3, page 127 for chemical profiles). Further fractionation was 
performed in order to determine the effects of the different polarities of the compounds 
present in the ethanol extract on the three cancer cell lines at a standardised concentration of 
25 µg/ml. A purified fraction (Chapter 2 section 2.2.1 page 25, fraction IV) comprising of 
four triterpenoid (cycloartane) compounds in major quantities and compounds 4 and 7 in 
minor quantities, as well as purified flavonoid fractions V and VI were also investigated at 5 
µg/ml for their anti-cancer activities. 
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Figure 7.5 The effect of fractions I to III (at 25 µg/ml), IV to VI (at 5 µg/ml) and 
compound 5 (at 5 µg/ml) on cancer cell viability over a 48 hour incubation period. 
 
The results of fractions I, II and III showed that a decrease in polarity of the compounds, 
found in the ethanol extract, also resulted in an increase of anti-cancer potential. On average 
the viability decreased by about 4 and 12% for the different cell lines for fraction I and 
fraction II, respectively. The non-polar compounds in fraction III (from the ethanol extract) 
exhibited an IC50 at 25 µg/ml for HL60 (more potent than that of etoposide which has an IC50 
at 46 µg/ml), whereas UACC62 and MCF7 cells demonstrated only a 14 and 9 % decrease in 
cell viability, respectively. When extract C was further fractionated, inhibitory effects of the 
compounds present in these fractions and the role these compounds play in the extract as a 
whole on the cancer cell lines could be observed. As such, this approach would help to 
establish if there was any chemically-mediated selection mechanism on the part of the cancer 
cells, for increasing their survival rates. This becomes apparent if effects of the fractions, on 
the three cell lines, are compared to the effects of the non-fractionated ethanol extract (see 
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Figures 7.2 – extract C and 7.4 – fraction I, II and III) - along with the aid of the chemical 
profiles in Appendix 2 page 122 and Appendix 3 page 126. There is an apparent dominant 
effect of the polar compounds (fraction I) over the non-polar compounds (fraction III), 
which could be responsible for the observed activities of the original non-fractionated ethanol 
extract (i.e., the polar compounds inhibit the activity of the non-polar compounds present in 
the ethanol extract). 
Purified fraction IV (at 5 µg/ml) had a similar effect on the three cancer cell lines as did 
fraction II (at 25 µg/ml) and the butanol extract. Purified fractions V and VI (at 5 µg/ml) 
exhibited a similar effect on these cells as for fraction I (at 25 µg/ml) and the aqueous 
extracts (V ≈ Ctrl). Thus, these observed effects could be related to the compounds 
(cycloartane- and flavonol- glycosides) present in the fractions and extracts.  
The interaction of the flavonol-type compounds found in fractions I, V and VI with the 
cancer cells, might be responsible for the increase in cancer cell viability comparable to that 
found with the aqueous extracts (see Figure 7.3, page 81). A synergistic effect of the 
cycloartane glycosides, on the decrease in cancer cell viability for HL60 and UACC62 cells, 
was observed at low concentrations; however MCF7 cells did not seem to exhibit a 
suppression of growth related to their survival in the presence of these compounds (V ≈ 
Ctrl). It has already been demonstrated that the triterpenoids (cycloartane glycosides) were 
found to be more potent anti-cancer agents than the flavonol-type compounds (as shown in 
Figure 7.5, page 85).  
Figure 7.5 also depicts the cancer cell viability response for compound 5, which displayed a 
slight increase in viability (V = 104.7 %) for HL60 cells, while MCF7 and UACC62 display 
on average a V = 98.4 %. A study done by Kikuchi and co-workers (2007), demonstrated the 
potent chemo-preventative effects of cycloartane-type triterpenoids on Epstein-Barr virus 
early antigen inhibition in TPA-induced Raji cells. The most potent inhibitory effects were 
found with the compounds that had a hydroxylated side chain on C-24 and a 3-oxo group. 
This configuration was found to be present in compounds 4, 5 and 6 of S. frutescens. 
Although at a low concentration of compound 5, a toxic chemo-preventative effect was not 
observed (Figure 7.5). 
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7.1.3.5 Summary 
In general, excluding fraction III for HL60 cells, the results showed that at 50 or 25 µg/ml, 
none of the extracts exhibited a profound impact on cancer cell viability; since the V ≥ 70 %, 
(i.e., these results did not show an Inhibitory Concentration of 50 %; IC50). These results 
therefore indicate that most of these extracts would not be effective as anti-cancer agents at 
these particular concentrations. The traditional extracts (A, B, D and K), have shown a 
greater tendency to favour the growth of the leukaemia cells at lower concentrations, 
compared to the organic extracts - which supported the growth of breast cancer cells. The 
non-polar compounds present in the ethanol extract displayed more potent anti-cancer 
activities than that of etoposide and could therefore be further examined for potential anti-
cancer drug applications against leukaemia. The triterpenoid and non-polar compounds 
present in S. frutescens were shown to have effected greater reduction in viability of cultured 
cancer cells than the flavonol glycosides (polar region), which are said to have anti-oxidant 
properties, rather than anti-cancer potential. In general, further targeted purification of 
selected fractions could result in more potent compounds being found. However the 
purification procedure needs to be optimised in order to obtain sufficient amounts of resulting 
compounds. 
  
7.2 QUANTIFICATION OF CYTOKINE RELEASE 
In order for immune cells to work effectively they need to be recruited to the sites of 
inflammation and appropriately activated. This is achieved by cellular receptors and 
associated cytokines that bind to these receptors. Cytokines are small molecular weight 
messenger proteins that are produced by cells of the immune system in response to a 
stimulus. They mediate interactions between cells, for example, communication between 
cells, may induce or suppress growth, differentiation and activation of cells, along with a 
variety of other functions. Generally, their role in health and diseases provides a key to the 
physiological importance of cytokines in cell-to-cell communication and their ability to 
regulate a wide spectrum of biological functions, including an immune response (Lydyard, 
Whelan and Fanger 2004; O‟Gorman and Donnenberg 2008; Parkin and Cohen, 2001). 
Cytokines can be classified according to the cells that produce them. These include 
interferons (IFN), tumour necrosis factor (TNF), interleukins (IL), lymphokines and 
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chemokines, which regulate the response to inflammation via the various cells of the immune 
system and their associated response to infections. Moreover, changes in cytokine profiles 
may serve as indicators of pathological conditions associated with diseases. Although the role 
of cytokines in the pathogenesis of human diseases is not yet fully understood, assays for 
cytokines have become a common feature in research and clinical laboratories (Lydyard, 
Whelan and Fanger, 2004; O‟Gorman and Donnenberg, 2008; Parkin and Cohen, 2001). 
With this background in place, a similar approach was followed to characterise the biological 
activity of selected extracts from S. frutescens. As such, this part of the study was focussed 
on measuring the effects of extracts made from S. frutescens on cytokine release by a HL60 
cell line at 25 µg/ml. The HL60 cell line was chosen due to its related characteristics with 
white blood cells associated with cytokines being released during an immune response (IR) to 
an invading pathogen. The amount of different cytokines released from these cells was 
measured using a commercial Cytometric Bead Array™ (BD Biosciences) kit. This kit was 
specifically developed to measure amounts of inflammatory cytokines, such as of IL1β, IL6, 
IL8, IL10, TNF and IL12p70, in the supernatants of stimulated immune cells. In this model 
system, an enhanced or suppressed plant extract driven trigger for cytokine release from 
HL60 cells in vitro would then be expected to parallel a similar situation of cytokines being 
released from counterpart immune cells in vivo.   
In order to control for cell viability factors, which may have influenced the outcome of 
cytokine release by stimulated cells, the results of cytokine release were also correlated with 
the cancer cell viability effects of S. frutescens extracts on cell lines UACC62, MCF7 and 
HL60 (see section 7.1 for cell viability and section 7.3 for cytokine and cell viability relation, 
pages 76 and 100). In order to simplify reference to the various plant extracts used from S. 
frutescens in this part of the study, extracts were numbered as followed: 
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Table 7.1 New codes representing the extracts, fractions and compound 5 tested in the 
assay for the release of cytokines. 
Number Extract code 
1 Control (Con.) 
2 PMA (12.5 ng/ml) 
3 Ethanol (extract C) 
4 C + PMA 
5 Fresh leaves (extract A) 
6 A + PMA 
7 Fresh stems (extract B) 
8 B + PMA 
9 Dry leaves (extract D) 
10 D + PMA 
11 Butanol (extract I) 
12 I + PMA 
13 DCM:MeOH (extract E) 
14 E + PMA 
15 Fraction I 
16 I + PMA 
17 Fraction II 
18 II + PMA 
19 Fraction III 
20 III + PMA 
21 Echinacea (Ech) 
22 Ech + PMA 
23 24 hour incubation extract C 
24 24H C + PMA 
25 Compound 5 Std. 
26 5 + PMA 
27 Fraction IV 
28 IV + PMA 
29 Fraction V 
30 V + PMA 
31 Fraction VI 
32 VI + PMA 
 
The cytokines IL1β, IL6, IL10, IL12p70, IL8 and TNF were tested in this assay due to their 
role in various pro- & anti-inflammatory actions involved in the first step of the IR i.e. 
inflammation. The subsequent graphs below present the amounts of the six cytokines released 
by the samples in the table above. 
7.2.1 The release of IL1β, IL6, IL10 and IL12p70 
The graphs below graphically present the effect the S. frutescens samples had on the release 
of IL1β, IL6, IL10 and IL12p70. The control (1) represented untreated HL60 cells and their 
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baseline level of cytokines being released into the cell culture supernatant under normal 
growth conditions i.e. without any additional chemical stimulation.  
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Figure 7.6a Release of IL1β, IL6, IL10 and IL12p70 cytokines for extracts and 
fractions I to III at 25 µg/ml for a 48 hour incubation period. 
 
In Figure 7.6b below, the reduced amount of cytokines IL1β, IL6, IL10 and IL12p70 (which 
vary from about 3 to 20 pg/ml) being released into the culture supernatant was also observed 
for samples 25 to 32 (fractions IV, V, VI and compound 5) similar to that of the extracts in 
Figure 7.6a above. 
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Figure 7.6b Release of IL1β, IL6, IL10 and IL12p70 cytokines for fractions IV, V, VI 
and compound 5 at 5 µg/ml for a 48 hour incubation period. 
 
The above graphs reflect the role the samples play in the release of four of the cytokines 
(IL1β, IL6, IL10 and IL12p70). Similar amounts of IL1β, IL6, IL10 and IL12p70 were 
released into the culture supernatant, relative to the control supernatant which had a 
concentration of 50.83 ± 7.74 pg/ml after a 48 hour incubation period. By contrast, when 
HL60 cells were exposed to different extracts from S. frutescens, there was a much lower 
amount of these cytokines released into the culture supernatant compared to the control and 
varied from 3 to 40 pg/ml. In addition, it was also observed that the S. frutescens samples, 
together with PMA, did not affect subsequent release of the four cytokines in the culture 
system. A study done by Ngcobo (2008) showed that high concentrations of aqueous and 
ethanol extracts of S. frutescens could reduce the production of IL1β and TNFα, which are 
regarded as being helpful in fighting muscle wasting in cancer and HIV/AIDS patients. 
However, where TNF and IL8 were concerned, there was a difference in the amounts 
released with and/or without co-stimulation by PMA.  
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It was observed that only in the cases when PMA was added to the cell culture system was 
there a higher production of IL8 and improvement of TNF being released into the 
supernatant. In light of these observations, the main focus of this discussion will be centred 
around the synergistic effects of the extracts of S. frutescens, co-stimulated with PMA, in 
HL60 cells on the subsequent release of IL8 and TNF cytokines. 
7.2.2 The release of TNF and IL8 induced by PMA 
Mitogens (PMA) are often used to stimulate lymphocytes and therefore can be used to assess 
immune responses in cells. According to Fortino et al. (2008) PMA was found to have either 
growth stimulatory or inhibitory effects on cultured cells, depending on which kind of cell 
was involved, including certain cancer cells. PMA has also been shown to induce expression 
of IL8, which in turn, can inhibit cell growth of PMA-induced HL60 cells (Oda et al., 2007). 
By this proposed mechanism, PMA could cause cells to undergo mitosis, thereby causing 
them to differentiate into the appropriate effector cells required for an appropriate IR. This 
kind of IR is usually exacerbated by the Pattern Recognition Receptors (PRR) present on the 
HL60 cells. This recognition mechanism is antigen-specific for a particular immunoglobulin 
released, but can also activate B cells, regardless of their antigenic specificity. The effect of 
PMA on the HL60 cells, after 6 hours of co-incubation, showed a decrease in cell viability, 
which could possibly be attributed to associated toxic effects of PMA itself, together with the 
lack of a proper Antigen Presenting Complex (APC) in the HL60 cell culture system used in 
this study, therefore resulting in a non-specific activation of anti-toxic defence mechanisms.  
As shown below in bar line 2 of Figures 7.7 and 7.8 (pages 95 and 97), PMA co-stimulated 
the release of TNF (130 ± 19.21 pg/ml) and IL8 (4552 ± 410.85 pg/ml) well above that of the 
baseline level. PMA forms part of the lipopolysaccharide (LPS) of Gram negative bacterial 
cells and can therefore, also be recognised by PRR present on the target cells used in this 
study. As such, the expression of TNF is stimulated by LPS interaction with PRR on the 
HL60 cell line. TNF activation is subsequently coupled with programmed cell death 
(apoptosis) initiated by infection with a particular pathogen and also coincides with release of 
inflammatory mediators which stimulate recruitment of other immune cells to the site of 
infection (Lydyard, Whelan and Fanger, 2004). The highest production of IL8 expression was 
found to be induced by interaction of PMA with PRR in monocytic cells, together with 
activated release of TNF. In general, this mechanism is believed to help the immune system 
to increase chemotaxis for neutrophils (as well as for T cells and basophils) at the site of 
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inflammation. With this principle in place, responses obtained from the addition of the plant 
extracts on the HL60 cells, with their subsequent cytokines released, will be discussed. 
7.2.3 Amounts of TNF and IL8 released by S. frutescens extracts with co-stimulation of 
PMA 
The following section presents the amounts of TNF and IL8 released in the presence of the 
samples 1 to 32. TNF release can be seen in Figures 7.7a and b, while IL8 release is 
presented in Figures 7.8a and b below, where all even numbers represent the samples with 
the addition of PMA and odd numbers represent the samples alone (Table 7.1, page 89). 
No significant increment in the release of all six cytokines (i.e., initiation of an immune 
response) was observed when the extracts of S. frutescens were applied to the HL60 cells 
without the co-stimulation of PMA. These observations could be related to the presence of 
GABA and pinitol (compounds 3 and 2, pages 10 and 9) found in Sutherlandia species. 
These compounds have been said to contribute to the improvement of wasting conditions 
experienced by cancer and HIV/AIDS patients, by the inhibition of the release of certain pro-
inflammatory cytokines, specifically TNF and IL1β (Tai et al., 2004; Ostlund and Sherman, 
1996; Mombereau et al., 2004). 
However, when the HL60 cells were co-stimulated with PMA, the S. frutescens extracts 
exhibited a greater release of TNF and IL8, relative to the baseline levels. Thus, the results 
below highlight the variation of TNF and IL8 concentrations relative to the baseline level for 
the release of cytokines by the HL60 cells, particularly when co-stimulated with PMA. 
 7.2.3.1 Amounts of TNF release 
Figures 7.7a and b below depict the differential release of TNF co-stimulated by PMA in the 
presence of extracts of S. frutescens. In all the cases where the extract, together with PMA 
was added to the cells, a resultant increased release of TNF was observed. This contrasted 
with the situation of TNF release by the cells cultured in the presence of PMA without extract 
being present. As such, the effect of S. frutescens extracts, on the target cells, was seen to 
occur mainly in association with extracts plus PMA. In essence, this observed effect, together 
with the release of specific cytokines into the culture supernatant, could be taken to mimick a 
possible in vivo situation of a bacterial infection in a given host, being combated by the 
release of appropriate cytokines. Sample number 20 (fraction III + PMA) exhibited the 
greatest increase in the release of TNF (approx. 230 pg/ml).  
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Figure 7.7a Release of TNF for extracts and fractions I to III at 25 µg/ml for a 48 hour 
incubation period. 
 
As with the similar pattern of the extracts as mentioned above (Figure 7.7a), it was observed 
that co-stimulation with PMA, resulted in an increase in the amount of TNF released with 
samples 25 to 32 (fractions IV, V, VI and compound 5) in Figure 7.7b below. 
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Figure 7.7b Release of TNF for fractions IV to VI and compound 5 at 5 µg/ml for a 48 
hour incubation period. 
 
The presence of PMA in the culture system coincided with the release of TNF (130 ± 19.21 
pg/ml), which might have been due to its related characteristics connected with a bacterial 
infection. All S. frutescens samples did not exhibit much of a response by themselves on 
subsequent TNF release by the culture system, but when PMA was present, a significant 
increase in the release of TNF was found.  
Addition of samples 26 to 32 to the cell culture system resulted in more TNF being released, 
similar to that obtained with fraction III, compared to other samples, but at a much lower 
relative concentration. The flavonoid fractions displayed a similar response in the in vitro 
culture system as was obtained with the aqueous extracts, together with PMA. As such, this 
activity could possibly be related to the presence of flavonol glycosides and their polar 
interactions with cells of the in vitro cell culture system. From these observations, it can 
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therefore be concluded that all compounds present in S. frutescens have an additive effect on 
the amount of TNF being released by the cultured cells in this system. This has provided 
further preliminary evidence to support the contention that extracts from S. frutescens could 
amplify the release of specific, immune-modulating cytokines by cells already stimulated by 
a pathogenic microorganism, such as a gram negative bacterium. As such, these extracts were 
observed to have an additive effect in helping the cells release more of a particular cytokine, 
thereby further assisting the elimination of a potential invasion with a bacterial pathogen. 
These results also suggested that the cultured cells needed to be intrinsically releasing certain 
cytokines, so that when the S. frutescens extracts were subsequently added to the HL60 cells, 
they were able to up regulate and release more of the particular cytokines involved in the IR.  
7.2.3.2 Amounts of IL8 released 
A similar trend of IL8 release, as for the release of TNF, just discussed, is depicted in the 
series of graphs (Figures 7.8a and b) below. The release of IL8 induced by the presence of 
the plant samples in the cell culture system together with PMA are represented by even 
numbers in the graphs below, while odd numbers represent the effect on the cultured cells in 
the presence of the samples without PMA (Table 7.1, page 89).  
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Figure 7.8a Release of IL8 for extracts and fractions I to III at 25 µg/ml for a 48 hour 
incubation period.  
As with TNF release, the highest amount of IL8 released was caused by sample number 20 
(Fraction III + PMA), which showed a release of 5967.93 ± 226.86 pg/ml. The release of 
IL8 caused by sample numbers 25 to 32 are depicted below.  
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Figure 7.8b Release of IL8 for fractions IV to VI and compound 5 at 5 µg/ml for a 48 
hour incubation period. 
 
An increase in IL8 will help in the recruitment of immune cells to the site of invasion by a 
pathogen in the process called chemotaxis. All of the test samples displayed a increase in the 
amounts of IL8 released relative to that of the control (1), however the amounts were less 
than that of the cells co-stimulated by PMA (number 2) alone (except number 20). The 
aqueous preparations (numbers 6, 8 and 10) and polar fractions (numbers 16, 30 and 32) 
displayed lower amounts of IL8 released, compared to the effect of the organic extracts. In 
comparison, sample number 20 (fraction containing non-polar compounds present in the 
ethanol extract in conjunction with PMA) and 28 (triterpenoid fraction with co-stimulation of 
PMA) caused a greater cytokine release. From the chromatogram of fraction IV (see 
Appendix 3 Figure 3.3, page 128) there was evidence for some non-polar and triterpenoid 
compounds occurring in this fraction, which might have caused a synergistic effect in 
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enhancing the response of the in vitro model system. The cycolartane glycosides, in a purified 
form, demonstrated a slightly lower amount (as seen with the response of compound 5). The 
results from Tian and co-workers (2005) implied that triterpenoids have potential anti-tumour 
properties by exerting their cytotoxic effects via apoptosis and G2/M cell cycle arrest.  
Addition of Fraction V to the culture system caused a release of IL8 at a concentration of 
3601.96 ± 229.4 pg/ml, while fraction VI showed a release of IL8 at a concentration of 
4231.76 ± 500.79 pg/ml. Fractions V and VI could thus be of value, boosting the IR, 
particularly when invading microorganisms need to be driven off, but they were not found to 
be as effective as the non-polar or triterpenoid compounds present in S. frutescens, due to the 
lower expression of IL8, which is necessary for chemotaxis of the immune cells, such as 
neutrophils, to the site of infection (Lydyard, Whelan and Fanger, 2004).  
A study done by Katerere and Eloff (2005) showed that free radical scavenging activity was 
present in the more polar extracts from S. frutescens after 30 minutes exposure. The release 
of free radicals has been reported by Haraguchi (2001) to play an adverse role in tissue injury 
and diseases. These scavenging activities of S. frutescens extracts may possibly explain its 
usefulness as a health tonic (Katerere and Eloff, 2005). Compounds with anti-oxidant 
activities have also been shown to enhance the immune system, by assisting the production 
and activity of cytotoxic immune cells, including enhanced expression of cancer suppressor 
gene products and associated inhibition of tumour angiogenesis (Shklar, 1998). Likewise, the 
inhibitory action of some compounds present in S. frutescens extracts on the release of certain 
pro-inflammatory cytokines, was also demonstrated by Tai et al. (2004); Ostlund and 
Sherman (1996) and Mombereau et al. (2004), all of which have been shown to be of value in 
the subsequent treatment of cachexia and wasting syndrome in cancer and HIV/AIDS 
patients. The decreased influence of S. frutescens extracts on the release of IL8, together with 
the co-stimulation by PMA in the in vitro cell culture system, provides further evidence 
related to the potential anti-oxidant attributes of the Sutherlandia extracts. 
7.2.4 Summary 
An absence in the release of certain pro-inflammatory cytokines, as measured in the in vitro 
cell culture system, provided further justification for anti-inflammatory and anti-oxidant 
effects related to Sutherlandia extracts alone. By inhibiting the action of TNF and IL1β, 
certain primary metabolites in S. frutescens, are said to contribute a reduction of the 
characteristic wasting syndrome experienced by cancer and HIV/AIDS patients (Ngcobo, 
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2008; Tai et al., 2004; Ostlund and Sherman 1996; Mombereau et al., 2004). Anti-
inflammatory agents have been shown to exhibit chemo-preventative activity (Surh et al., 
2001; Surh, 2002); therefore, the anti-inflammatory properties which have also been 
attributed to S. frutescens could possibly be used in a chemo-preventative setting as well. 
However, the differential increase in TNF and IL8, together with the co-stimulation by PMA, 
could also contribute to possible immune-stimulating effects. For this reason, preparations of 
Sutherlandia seem to exhibit many attributes that could be related to the complex nature of 
compounds present in the raw plant material. Possible synergistic effects between these 
compounds present in the extracts of S. frutescens, most likely justify its various traditional 
uses.  
Fraction III and IV exhibited the greatest increase in TNF and IL8 (with the co-stimulation 
of PMA) which has provided evidence that the in vitro immune-stimulating properties of S. 
frutescens extracts could possibly be due to the presence of non-polar compounds found in 
the ethanol extract and the triterpenoid compounds. According to the results, these fractions 
could be considered a good target for future investigations into possible in vivo immune-
modulating properties, particularly in view of the observed decrease in cancer cell viability 
(although marginal for fraction IV) but also associated with an increase in the release of 
cytokines, as measured in the in vitro cell culture system. The compounds present in these 
fractions displayed a synergistic action on the resultant increased release of cytokines by the 
HL60 cells. Further purification might cause a reduction in its anti-cancer properties but an 
increase in cytokine release should not be affected as seen with the response of compound 5. 
(a slight increase in cancer cell viability, together with release of cytokines).  
 
7.3 INTEGRATED DISCUSSION OF ANTI-CANCER AND CYTOKINE RELEASE 
IN THE PRESENCE OF PLANT EXTRACTS 
In this section the net total affects of the S. frutescens extracts, with and/or without PMA co-
stimulation on cancer cell viability and release in cytokines, simultaneously will be presented. 
The cytokine release assay was tested only, at 25 µg/ml, thus the comparison of the 
corresponding extracts influence on cancer cell viability will be done for the same 
concentration. 
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7.3.1 Immune-stimulating properties 
Vaccination of foreign microorganisms and/or adjuvants into the body sets the immune 
system in action to organise defensive mechanisms for the host‟s survival. Thus, the PMA 
treatment showed an increase in the release of cytokines (see Figures 7.7 and 7.8, pages 94 to 
98). From the results of PMA (Figures 7.1, 7.7 and 7.8) it was observed that PMA could play 
a dual role in a cellular system by indicating anti-cancer properties (which might be due to 
the toxicity of PMA and lack of APC on the cancer cells) and increasing cytokine 
expressions. 
The most active extract that was observed, at 25 µg/ml, for possible in vitro immune-
modulating properties was the ethanol extract (Ext C) with PMA co-stimulation (Figures 
7.7a and 7.8a number 4). Further fractionation of this extract showed the non-polar portion of 
the ethanol extract with PMA co-stimulation (see number 20 in Figures 7.7b and 7.8b) 
exhibited the maximum amount of release of TNF and IL8 (even higher than that of the net 
ethanol extract‟s impact; see Figures 7.2 and 7.5, pages 79 and 85). This provided 
preliminary evidence that the active compounds which displayed the most profound in vitro 
immune-stimulating response and anti-cancer influence in the ethanol extract were part of the 
non-polar fraction of this extract. The triterpenoid-rich fraction (Fraction IV) also displayed 
a slight decrease in cancer cell viability and increased amount of the release in cytokines 
when co-stimulated with PMA at a lower concentration, therefore these compounds could 
also contribute to the activity related to S. frutescens. 
The aqueous preparations were shown to exhibit an increase in cell viability (see Figure 7.3, 
page 81) and release in cytokines with the co-stimulation of PMA (see Figures 7.7a and 7.8a 
numbers 6, 8, 10 and 14) on the various cancer cell lines. The polar compounds present in 
these preparations might suppress the replication of PMA and thus resulted in less PMA in 
the body so the in vitro IR was not as high as the ethanol extract and only a small amount of 
immune cells were recruited therefore a decrease in the release of cytokines relative to PMA 
co-stimulation was observed. This showed a good response for helping the immune system in 
conserving energy. In contrast, as shown in Figure 7.3, due to the unique characteristics of 
the cancer cells and/or the non toxic nature of these compounds, these extracts also promoted 
cancer cell growth which might have been further caused by the multifunctional role of IL8 
in the cancer cells i.e., neutrophils that are attracted by IL8 could lead to the release of 
proteases, heparin and enzymes that are involved in the degradation of the extracellular 
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matrix, resulting in metastasis of the tumour. This, in turn, may have contributed towards 
tumour aggressiveness through the promotion of invasion and angiogenesis (Yao et al., 
2007). Due to these observations, there is preliminary evidence that these extracts should 
probably not be taken when a patient has cancer as they may contribute to the aggressiveness 
of the cancer (at low concentrations) instead of helping the immune system to fight off the 
cancer. These extracts did still increase the expression of TNF, therefore, there was still an 
initiation of inflammation but due to the possible enhancement of tumour aggressiveness and 
angiogenesis, the cancer cells would probably overpower the effect of TNF thus resulting in a 
net increase in cell viability. The butanol and Echinacea extracts exhibited some anti-cancer 
and immune-stimulating properties but were not as effective as the non-polar portion of the 
ethanol extract. The table below provides a brief summary of the cancer cell viability and 
amounts of cytokines released to clearly compare the effects as discussed above. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
103 
Table 7.2 A summary of cancer cell viability and amount of cytokines released for all 
extracts, fractions and compound 5. 
 
Extracts 
 
Concentratio
n (µg/ml) 
 
Incubation 
time (hours) 
 
Viability for 
HL60 cells (%) 
Cytokine expression for 
extracts with PMA (pg/ml) 
TNF IL8 
Control No drug 48 100  50.83 ± 7.7 50.83 ± 7.7 
PMA 12.5 ng/ml 6 86.4 ± 9.22 129.7 ± 19.2 4551.9 ± 410.8 
Extract A 25 48 113.0 ± 4.0 176.1 ± 34.3 3333.9 ± 254.6 
Extract B 25 48 110.3 ± 4.0 159.1 ± 53.1 3372.8 ± 180.2 
Extract I 25 48 94.1 ± 0.2 172.5 ± 11.7 3600 ± 184.8 
Extract C 25 48 97.7 ± 7.6 184.4 ± 44.5 4449.6 ± 291.6 
Extract D 25 48 110 ± 7.2 152.4 ± 24.8 3168.3 ± 252.5 
Extract E 25 48 115.3 ± 4.9 196.1 ± 33.1 3968.6 ± 87.4 
Fraction I 25 48 96.7 ± 1.1 179.2 ± 51.2 2909.5 ± 257.1 
Fraction II 25 48 80.3 ± 3.4 179.5 ± 58.1 3916.6 ± 817.2 
Fraction III 25 48 50.5 ± 3.3 229.4 ± 13.9 5967.9 ± 226.9 
Ech 25 48 100.2 ± 7.4 180.1 ± 57.8 3260.9 ± 250.4 
Fraction IV 5 48 91.5 ± 1.8 180.2 ± 35.4 5277.7 ± 541.9 
Fraction V 5 48 106.1 ± 2.9 194.9 ± 31.4 3602 ± 229.4 
Fraction VI 5 48 106.3 ± 3.3 164.3 ± 47.6 4231.8 ± 500.8 
Compound 5 5 48 104.7 ± 0.04 206.4 ± 48.4 3846.8 ± 262.1 
 
7.4 CYTOTOXICITY EFFECTS OF SUTHERLANDIA  
There is a fine line between inflammation and cancer progression. Studies have shown that 
chronic inflammation is a progenitor of tumour progression and that many cancers have been 
found to arise from sites of infection, chronic irritation and inflammation. Factors such as 
TNF and the interleukins may also serve as connecting links between inflammation and 
cancer. Dysregulation and overproduction of these can lead to cancer and other diseases 
(Yadav et al., 2010). This raises a few questions as to whether S. frutescens preparations will 
contribute to the progression of tumour cells while being administered to cancer patients in 
clinical trials. In order to answer this essential question, the study continued with a 
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preliminary cytotoxicity experiment, which was done in collaboration with Dr S. Barichievy 
from the Synthetic Biology group of CSIR. Macrophages from whole blood were isolated and 
one extract, chosen on the basis of its cancer cell viability and amount of cytokines released, 
was added to the macrophage cells to determine the cell viability after S. frutescens addition 
using the SRB assay. This was conducted using the same procedure as the cell viability 
experiment for the cancer cells.  
Extract A (aqueous extract of the fresh leaves) was chosen because it showed an increase in 
cancer cell viability at 25 µg/ml and a decrease in cancer cell viability at 100 µg/ml for all 
three cell lines (see Figure 7.3, page 81) and at 25 µg/ml it shows an increase in TNF and 
IL8 expressions (see Figures 7.7a and 7.8a, pages 94 and 97). To determine the effects of 
this extract on macrophage immune cells would provide evidence as to whether S. frutescens 
is cytotoxic to the immune cells at the same concentrations. The graph below shows the 
macrophage and HL60 cell viabilities for 25 and 100 µg/ml. 
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Figure 7.9 Macrophage and HL60 cell viability after exposure with extract A at 100 and 
25 µg/ml for a 48 h incubation period. 
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Extract A illustrated an increase in cancer cell viability at 25 µg/ml and a decrease at 100 
µg/ml but the effect on macrophage cell viability increased at both concentrations (V = 
208.03 and 197.28 % at 25 and 100 µg/ml respectively). From these observations it can be 
stated that S. frutescens was not cytotoxic to the macrophage cells, favoured their survival 
and growth and displayed selectivity for immune cells. These results are supported by 
Ngcobo (2008) who also found that aqueous extracts were not cytotoxic to normal T cells. 
Nbcobo (2008) also showed that the ethanol extract induced proliferation in the T cells after 
24 hours but had the opposite effect after 48 hours, while the aqueous extract significantly 
increased the T cell viability only after 48 hours of exposure. The results concluded that 
higher concentrations could be toxic to the normal T cells while lower concentrations of S. 
frutescens could stimulate the immune cells. To conclude, the above observations give reason 
to suggest that if S. frutescens was to be administered to cancer patients, at the correct 
dosages and time intervals, it could possibly have an additive effect on the immune cells of 
the body and increase their numbers so that there would be more cells to help fight off the 
invading microorganisms.  
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PART 2 CONT. 
CHAPTER 8 
CONCLUSION 
 
Sutherlandia frutescens has a long history of medicinal use in southern Africa and has been 
widely used for many various ailments including diabetes, stress, fever, internal cancers and 
more recently HIV/AIDS (Van Wyk and Albrecht, 2008; Van Wyk, Van Oudtshoorn and 
Gericke, 2009; Ojewole, 2008). The primary aim of this research was to phytochemically 
characterise the various extracts made from S. frutescens. Due allowance was made for 
various extract preparation methodologies, which ranged from traditional methods to other 
more scientifically acceptable methods using organic solvents. The chemical profiles were 
obtained by HPLC analysis where the various regions were identified and two compounds 
were isolated and purified from the plant material (using various column chromatographic 
techniques). The structures of these two compounds, along with one of the standards were 
successfully elucidated using the NMR spectroscopic and mass spectrometric techniques. 
Using UPLC-TOF-MS techniques and ChemSketch optimised for 3D viewing, a structural 
analysis prediction was achieved for the flavonoid fractions that were not purified completely.  
The chemical profiles of the six S. frutescens plant samples were analysed on the HPLC 
instrument and it was noted that various differences were present pointing to the possible 
presence of chemotypes. 
The purpose of the second part of the study was to connect the compounds present in the 
extracts to the possible immune-modulating and anti-cancer abilities of S. frutescens. Using a 
three cell line panel screen with melanoma, breast and leukaemia cell lines and a cytokine up 
regulating assay could help to preliminary ascertain whether this traditional medicinal plant 
could possibly have anti-cancer and/or immune-modulating properties and which compounds 
(present in the extracts and singularly) could be responsible for these actions. 
With the background chemistry of the extracts and compounds in place, the SRB assay was 
used to determine cancer cell viability for the Sutherlandia preparations. The effects of the 
extracts were studied over a 48 hour incubation period and it was found that the organic 
extracts were shown to be more effective at decreasing the cancer cell viability than the 
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traditional extracts. From the ethanol preparation, the non-polar portion contributed more to 
the potency on the cancer cell lines displaying an IC50 at a concentration of 25 µg/ml, which 
was more potent than etoposide (IC50 46 µg/ml) against the leukaemia cell lines. 
HPLC-MS provided confirmation that the ethanol extract contained a higher concentration of 
the non-polar compounds and triterpenoids together as compared to the other extracts, 
therefore its strong anti-cancer activities could be related to the presence of these compounds. 
The aqueous extracts of the fresh and dry plant material contained a higher concentration of 
the polar compounds, which were found to exhibit lower anti-cancer properties at lower 
concentrations. For the aqueous extracts to be effective against cancer the optimal dose and 
duration should be increased. The flavonol glycosides were found in the polar regions of the 
extracts and exhibit anti-oxidant properties. The butanol portion of the methanol extract 
contained the highest concentration of the cycloartane glycosides found in S. frutescens and 
exhibited similar anti-cancer properties to the ethanol extract.  
From the cytokine expression assay, only TNF and IL8 were increased with the addition of 
PMA and the extracts together (relative to the control). All the Sutherlandia preparations 
increased the release of TNF and IL8 (with co-stimulation by PMA), but the greatest increase 
was that of the ethanol extract. Furthermore the non-polar fraction from the ethanol extract 
was mainly due to this activity. The interaction of these non-polar compounds with our 
immune system was favourable and was able to preliminary assist the cells of the immune 
system to increase the amount of the necessary cytokines being released. Organic 
preparations of S. frutescens were more effective than the traditional preparations. S. 
frutescens alone did not affect the in vitro model system in assisting the release of cytokines, 
but rather when the body was undergoing an IR, the addition of an ethanolic preparation of S. 
frutescens to the diet could have possibly assisted the body in fighting the disease. This could 
be of great interest for treatment of diseases that specifically attack the immune system, such 
as HIV/AIDS and cancer, as the body only needs to recognise the need for an IR and 
supplementation with Sutherlandia could possibly increase the production of the molecules 
necessary for the immune response to be effective. This resulted in a more rapid expulsion of 
the invader organism and limited the likelihood of the infectious organism from spreading to 
other cells.  
From these observations an ethanolic preparation would probably been the best choice as a 
herbal remedy for stimulating the immune system. In essence, this in vitro cell culture system 
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has proved useful in demonstrating the nature of the cells in relation to their interactions with 
the compounds present in the plant extracts and associated solvent systems, particularly with 
regard to differential cell survival patterns. 
HPLC-MS analysis made it possible to determine that the non-polar and triterpenoid 
compounds were mainly present in high concentrations in the extracts and fractions that were 
effective against the cancer cell lines and at stimulating the in vitro immune system.  
Some semi-synthetic analogues of anti-cancer drugs that have been isolated from plants were 
active against numerous cancer cells. However, most of these compounds failed as effective 
drugs because of their non-specific toxicity to both, normal and cancer cells, as well as 
bioavailability problems (Ayres and Loike, 1990). S. frutescens has shown potential as an 
anti-cancer remedy due to the selectivity index present when tested on macrophage cells 
derived from whole blood. A single extract was tested and exhibited no cytotoxicity towards 
the macrophage cells while at the same time showed potential anti-cancer abilities against all 
three cell lines. 
If Sutherlandia could be administered to cancer patients there is reason to suggest that it 
could possibly have an additive effect on the immune cells of the body by increasing their 
numbers and amount of cytokines produced so that there would be more cells activated and 
produced to help fight off infectious microorganisms. To conclude, S. frutescens could be of 
value for developing an anti-cancer remedy due to the increase in viability of macrophage 
cells as compared to the cancer cells. However, it was shown that Sutherlandia did not illicit 
an IR in the absence of an immunological stimulus.  
 
RECOMMENDATIONS: 
In order to clearly determine the effective concentration of these extracts, fractions and 
compounds to achieve optimal anti-cancer and immune-stimulating effects, a dose response 
curve should ideally have been done on all samples to determine the IC50 values. To 
determine if a single compound could be responsible for the anti-cancer and immune-
stimulating properties, a targeted purification approach should be followed in future. Due to 
the complex nature of the compounds, it is of utmost importance to determine an effective 
isolation and purification technique to optimise the phytochemical process. 
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Further investigations into the role S. frutescens plays in its medicinal properties, both in vitro 
and in vivo, should be done. Further cytotoxicity assays should be carried out on the extracts 
and isolated compounds to determine the therapeutic index. A study on drug interactions of 
Sutherlandia should also be investigated to determine the efficiency when taken in 
collaboration with drugs used for HIV/AIDS and cancer patients, such as anti-retrovirals and 
chemo-preventative drugs. 
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APPENDICES 
 
APPENDIX 1 
PLANT IDENTIFICATION 
 
Appendix Figure 1.1 SANBI Identification. 
122 
APPENDIX 2 
EXTRACT CHROMATOGRAMS 
 
 
 
Appendix Figure 2.1 The ESI
+
, ESI
-
 and UV chromatograms for extract C with the 
regions and compounds 4, 5 and 7 labelled in negative mode (refer to page 33). UV-VIS 
detection done scanning from 200 to 600 nm. 
 
 
123 
 
Appendix Figure 2.2 The ESI
-
 chromatograms for extracts A,  B and K (refer to page 
34). 
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Appendix Figure 2.3 The ESI
-
 chromatograms for extracts F, G, H, I and J. Refer to 
page 35 for explanation. 
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Appendix Figure 2.4 The ESI
-
 chromatograms for extracts C, D and E. Refer to page 35 
for explanation. 
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APPENDIX 3 
FRACTION DATA 
 
 
Appendix Figure 3.1 The ESI
+
 chromatograms for fractions I, II and III. refer to page 
36. 
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Appendix Figure 3.2 The ESI
+
 chromatograms for fractions IV, V and VI. Refer to page 
36.  
128 
 
Appendix Figure 3.3 Mass spectral data (ESI
-
 and ESI
+
) of peak eluting at 24.73 min. 
from fraction V which corresponds to that of compounds 10 or 11 is displayed above 
from the SQD system. Refer to pages 36 and 37 for explanations. 
129 
 
Appendix Figure 3.4 Mass spectral data (ESI
-
 and ESI
+
) of peak eluting at 21.25 min. 
from fraction VI which corresponds to that of compounds 8 or 9 from the SQD system. 
Refer to pages 36 and 37 for explanations. 
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Appendix Figure 3.5 UV absorption spectra of peaks eluting at 24.65 and 25.43 minutes 
in fraction V from the SQD system (scanning from 200 to 600 nm). Refer to page 36. 
 
Appendix Figure 3.6 UV absorption spectra of peaks eluting at 21.15 and 22.17 minutes 
in fraction VI (scanning from 200 to 600 nm). Refer to page 36. 
131 
 
Appendix Figure 3.7 3D representations of compounds 8 to 11 showing the sugar 
regions and the space occupied by each using ChemSketch 12 (refer to page 39). 
 
Appendix Figure 3.8 WATERS synapt UPLC chromatogram (HRTOF MS ESI
-
 mode) 
with proposed order of elution of the four flavonoid compounds 8 to 11 (refer to page 
39).
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APPENDIX 4 
COMPOUND DATA 
 
Compound 5 
 
Appendix Figure 4.1 UPLC chromatogram for compound 5 (HRESI
-
 and HRESI
+
). 
Refer to page 42. 
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Appendix Figure 4.2 HRTOFMS (ESI
-
 and ESI
+
) spectra for the standard of compound 
5 from the QTOF system. Refer to page 45. 
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Compound 4 
 
Appendix Figure 4.3 UPLC chromatogram for compound 4 (HRESI
-
 and HRESI
+
). 
Refer to page 46. 
 
Appendix Figure 4.4 HRTOFMS (ESI
-
 and ESI
+
) for compound 4 from the QTOF 
system. Refer to page 48. 
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Appendix Figure 4.5 ESI mass spectra (ESI
-
) for compound 4 showing the formic acid 
adduct from the SQD system. Refer to page 50. 
 
Appendix Figure 4.6 ESI mass spectra (ESI
+
) for compound 4 showing the sodium and 
potassium adducts from the SQD system. Refer to page 51. 
136 
Compound 7 
 
Appendix Figure 4.7 UPLC chromatogram for compound 7 (HRESI
-
 and HRESI
+
). 
Refer to page 53. 
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Appendix Figure 4.8 HRTOFMS (ESI
-
 and ESI
+
) for compound 7 from the QTOF 
system. Refer to page 55. 
 
Appendix Figure 4.9 Mass spectral data for compound 7 showing the sodium and 
potassium adducts formed in positive mode of ESI from the SQD system. Refer to page 
55. 
138 
 
Appendix Figure 4.10 UV data for compounds 5, 4 and 7 from the QTOF system 
(scanning from 200 to 600 nm). Refer to page 57. 
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APPENDIX 5 
NMR DATA 
 
Compound 5 
 
Appendix Figure 5.1 C
13
 NMR spectrum for compound 5 (600 MHz Varian NMR in d-
pyridine). Refer to page 44. 
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Appendix Figure 5.2 H
1 
NMR spectrum for compound 5 (600 MHz Varian NMR in d-
pyridine). 
141 
Compound 4 
Appendix Figure 5.3 C
13 
NMR spectrum for compound 4 (600 MHz Varian NMR in d-
methanol). Refer to page 48. 
Appendix Figure 5.4 H
1 
NMR spectrum for compound 4 (600 MHz Varian NMR in d-
methanol).  
142 
Compound 7 
Appendix Figure 5.5 C
13 
NMR spectrum for compound 7 (600 MHz Varian NMR in d-
methanol). Refer to page 55. 
Appendix Figure 5.6 H
1 
NMR spectrum for compound 7 (600 MHz Varian NMR in d-
methanol). 
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Various 2D data processed 
HSQC of compound 4 
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HMBC of compound 7 
 
COSY of compound 5 
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APPENDIX 6 
SIX S. FRUTESCENS SAMPLE DATA 
 
Appendix Figure 6.1 Full chemical profiles (ESI
-
 chromatograms) for clone samples I to 
VI and the reference material (MeOH extract). Refer to page 65. 
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APPENDIX 7 
DATA GENERATED FOR BIOLOGICAL SCREENINGS 
 
Appendix Table 7.1 Anti-cancer assay data results calculated with standard deviations 
(SD). Statistical analysis n = 2. Refer to pages 76 to 87. 
SAMPLES (µg/ml) UACC62 SD MCF7 SD HL60 SD
Ctrl 100 0 100 0 100 0
Extract A (100) 23.48407 0.04494 32.37519 2.89024 18.35066 2.05154
Extract A (50) 87.6565 1.85875 92.69469 5.7216 100.11704 1.38385
Extract A (25) 102.96765 2.10564 94.01483 7.78995 113.01877 4.01386
Extract B (100) 33.69003 1.71352 37.83866 3.11077 19.13639 8.44171
Extract B (50) 87.58415 0.07181 72.16467 3.9936 99.19836 13.13688
Extract B (25) 99.07113 5.80248 85.95438 1.34174 110.29158 3.95349
Extract C (100) 47.53136 0.55679 42.83491 2.69765 16.38217 18.63402
Extract C (50) 82.98204 1.86738 90.33509 2.61133 81.31711 7.65688
Extract C (25) 90.28356 1.33388 104.71191 2.69874 97.74518 7.63003
Extract D (100) 60.28127 3.28024 55.43637 0.39913 70.15985 17.71078
Extract D (50) 90.83639 3.38421 66.65241 4.17172 105.32235 0.80622
Extract D (25) 97.844 6.12998 89.34703 2.29034 109.99995 7.24951
Extract E (50) 86.44057 1.48451 81.84864 1.65842 95.65806 4.78073
Extract E (25) 99.07443 2.20003 105.14393 3.6159 115.27623 4.89714
Extract F (100) 59.15935 5.75346 62.19129 10.45318 32.64957 4.22293
Extract F (50) 77.91523 3.67983 117.92915 8.09439 96.7739 4.64393
Extract F (25) 85.33684 8.19225 126.50605 18.94846 133.17079 5.09545
Extract G (100) 48.93725 7.94231 44.38272 0.15353 22.85188 6.00007
Extract G (50) 85.84547 0.75865 114.04423 0.62541 76.60875 7.03748
Extract G (25) 95.41544 1.77026 128.96535 2.61178 87.97124 6.52025
Extract H (100) 7.41766 0.01602 5.45407 2.4754 5.00611 2.25057
Extract H (50) 72.79403 3.46097 58.45799 3.58834 53.95347 2.2427
Extract H (25) 95.11126 7.55796 122.70151 3.40399 84.05935 5.15066
Extract I (100) 16.78041 2.75994 32.43819 0.02848 12.7739 0.6705
Extract I (50) 80.40379 2.00504 123.35906 5.2609 80.87556 7.1187
Extract I (25) 97.76921 2.13162 142.66677 1.21836 94.0724 0.24455
Extract J (100) 58.85738 2.37813 48.87008 1.20663 13.85412 11.66793
Extract J (50) 90.97793 2.01284 67.77294 2.35168 81.01717 0.89438
Extract J (25) 100.78209 2.11408 88.57625 1.23345 91.26911 3.37189
Extract K (100) 45.50335 6.06549 46.43662 0.91167 36.01832 2.49817
Extract K (50) 91.0577 2.93531 86.49719 4.12504 109.21898 0.88115
Extract K (25) 97.03052 3.0347 102.87426 3.49163 120.85974 8.18933
Fraction i (25) 94.79116 1.95379 98.68143 1.68232 96.71377 1.06085
Fraction ii (25) 87.66729 1.20318 97.59378 0.10452 80.29478 3.86201
Fraction iii (25) 86.28014 4.26566 91.00992 0.11693 50.46192 3.28457
Fraction iv (5) 90.28384 1.91369 97.57541 0.3921 91.51932 1.81187
Fraction v (5) 94.35947 3.00776 98.87651 0.01843 106.05186 2.90202
Fraction vi (5) 93.82518 1.99376 100.20876 0.48751 106.27041 3.3049
Compound 5 (5) 97.16235 3.28054 99.66922 0.31989 104.6595 0.03862
% Viability results
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Appendix Table 7.2 Cytokine assay data calculated with standard deviations (SD). Statistical analysis n = 4. Refer to pages 87 to 99. 
IL1β SD IL6 SD IL10 SD IL12p70 SD TNF SD IL8 SD
1 Control 50.83 7.73706 50.83 7.73706 50.83 7.73706 50.83 7.73706 50.83 7.73706 50.83 7.73706
2 PMA 14.86 3.6911 10.37 1.30108 11.21 1.54149 19.29 1.14551 129.69 19.2106 4551.95 410.8487
3 Ext C ethanol 5.62 0 0 0 0 0 0 0 0 0 50.4125 8.72949
4 C + PMA 8.40333 5.61513 7.67 1.89505 8.815 2.41123 14.075 4.02344 184.3675 44.50132 4449.638 291.5709
5 Ext A (aq fresh leaf) 0 0 0 0 0 0 0 0 0 0 43.965 18.3664
6 A + PMA 14.69 0.39598 9.615 0.07778 11.9 1.76777 19.29 1.14551 176.1425 34.28128 3333.85 254.626
7 Ext B (aq fresh stem) 0 0 0 0 0 0 0 0 0 0 38.72 6.61508
8 B + PMA 15.36 1.86676 10.465 0.16263 10.85 0.28284 17.305 1.09602 159.12 53.0709 3372.813 180.1947
9 Ext D (aq dry leaf) 0 0 0 0 0 0 0 0 0 0 47.5375 9.56774
10 D + PMA 16.605 4.65983 10.435 1.54856 13.175 1.63342 18.97 3.97394 152.3975 24.77091 3168.28 252.5174
11 Ext I (butanol) 7.09667 4.25187 6.92 0 5.585 1.492 8.15333 3.92826 4.8125 2.23284 38.145 6.08923
12 I + PMA 5.085 2.11425 3.07 0.07071 0 0 6.84 0.42426 172.4875 11.73381 3600.035 184.7743
13 Ext E (DCM:MeOH) 11.2 0 6.33 0 8.96 0 10.25 0 5.02667 3.33708 43.95 10.18165
14 E + PMA 4.01667 1.24134 3.02 0 4.53 0 6.14333 0.68705 196.1375 33.12863 3968.628 87.37321
15 Fraction i 4.215 1.98697 0 0 0 0 0 0 4.385 0.36062 29.50333 2.59643
16 i + PMA 3.22 0 0 0 0 0 5.05 0 179.23 51.20867 2909.5 257.0757
17 Fraction ii 7.55 0.45255 5.185 0.79903 4.885 0.16263 8.745 0.10607 4.79 2.40504 42.24 10.62793
18 ii + PMA 5.29 0 5.09 0 0 0 6.54 0 179.5175 58.06748 3916.568 817.1514
19 Fraction iii 5.93 1.70994 4.62 0 6.05 0 7.07333 2.54449 4.72 3.22308 163.5725 40.50969
20 iii + PMA 5.35333 2.16569 4.435 1.05359 5.235 1.98697 7.27333 2.59257 229.445 13.89247 5967.925 226.8568
21 Echinacea 5.265 1.85969 3.445 0.74246 4.77 0 6.1 2.54558 4.54667 1.51398 33.54 3.564
22 Ech + PMA 4.63333 0.33501 3.965 0.13435 4.53 0 6.04333 0.91106 180.1225 57.76763 3260.92 250.3971
23 24H EtOH 9.08 4.3428 7.54 1.15966 8.72 1.24451 11.12 4.52607 7.96 2.46246 69.27 2.28171
24 24H EtOH + PMA 5.13 2.43358 4.62 0 4.77 0 6.095 1.47785 166.78 7.15367 4002.553 414.8947
25 Compound 5 0 0 0 0 0 0 0 0 0 0 53.745 29.64469
26 5 + PMA 18.22 5.38815 11.64 3.40825 15.105 4.75883 20.1 6.1094 206.405 48.44754 3846.77 262.1111
27 Fraction iv 3.59 0 0 0 0 0 0 0 3.1 0 73.9075 16.00801
28 iv + PMA 14.115 3.62746 10.045 3.83959 11.135 3.25976 17.48 5.47301 180.1725 35.36543 5277.695 541.9048
29 Fraction v 0 0 0 0 0 0 0 0 0 0 44.9325 19.09687
30 v + PMA 13.71333 9.52696 11.715 2.5668 15.035 5.81949 16.07667 11.47788 194.93 31.41209 3601.96 229.3982
31 Fraction vi 4.3 0 0 0 0 0 5.5 0 4.72 0 39.9775 9.05988
32 vi + PMA 14.97 6.64017 9.58667 5.86989 12.34333 7.91975 17.86333 9.1225 164.28 47.64315 4231.76 500.7884  
